CN111440174B - Pyridine amide compound and preparation method and application thereof - Google Patents
Pyridine amide compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN111440174B CN111440174B CN202010257388.9A CN202010257388A CN111440174B CN 111440174 B CN111440174 B CN 111440174B CN 202010257388 A CN202010257388 A CN 202010257388A CN 111440174 B CN111440174 B CN 111440174B
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- fluoro
- pyrazolo
- methyl
- methoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Pyridine amide compound Chemical class 0.000 title claims abstract description 174
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 218
- 238000003786 synthesis reaction Methods 0.000 claims description 217
- 239000000543 intermediate Substances 0.000 claims description 193
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 102
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 59
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 44
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims description 35
- BSWQUGLDVWBJGW-UHFFFAOYSA-N 7-(2-fluoro-4-nitrophenoxy)-5-methylpyrazolo[1,5-a]pyrimidine Chemical compound CC1=NC=2N(C(=C1)OC1=C(C=C(C=C1)[N+](=O)[O-])F)N=CC=2 BSWQUGLDVWBJGW-UHFFFAOYSA-N 0.000 claims description 23
- CSVSURSIOXXMGL-UHFFFAOYSA-N N1=C(C)C=C(O)N2N=CC=C21 Chemical compound N1=C(C)C=C(O)N2N=CC=C21 CSVSURSIOXXMGL-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- TUXKCEHRWWVAOF-UHFFFAOYSA-N 3-fluoro-4-(5-methylpyrazolo[1,5-a]pyrimidin-7-yl)oxyaniline Chemical compound CC1=NC2=CC=NN2C(=C1)OC3=C(C=C(C=C3)N)F TUXKCEHRWWVAOF-UHFFFAOYSA-N 0.000 claims description 20
- BJXJEUOXFCAJLA-UHFFFAOYSA-N 7-chloro-5-methylpyrazolo[1,5-a]pyrimidine Chemical compound N1=C(C)C=C(Cl)N2N=CC=C21 BJXJEUOXFCAJLA-UHFFFAOYSA-N 0.000 claims description 20
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- OOYDYTNRVMWHHA-UHFFFAOYSA-N 6-ethyl-7-(2-fluoro-4-nitrophenoxy)-5-methylpyrazolo[1,5-a]pyrimidine Chemical compound CCC1=C(N2C(=CC=N2)N=C1C)OC3=C(C=C(C=C3)[N+](=O)[O-])F OOYDYTNRVMWHHA-UHFFFAOYSA-N 0.000 claims description 17
- HGHYOMNZKJZSSG-UHFFFAOYSA-N 7-(2-fluoro-4-nitrophenoxy)-5,6-dimethylpyrazolo[1,5-a]pyrimidine Chemical compound CC1=C(N2C(=CC=N2)N=C1C)OC3=C(C=C(C=C3)[N+](=O)[O-])F HGHYOMNZKJZSSG-UHFFFAOYSA-N 0.000 claims description 17
- 239000012265 solid product Substances 0.000 claims description 17
- VFJDCEYJBRMOBL-UHFFFAOYSA-N 4-(5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)oxy-3-fluoroaniline Chemical compound CC1=C(N2C(=CC=N2)N=C1C)OC3=C(C=C(C=C3)N)F VFJDCEYJBRMOBL-UHFFFAOYSA-N 0.000 claims description 16
- PFLIREYJPZDIDR-UHFFFAOYSA-N 7-chloro-5-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=NN2C(Cl)=C1 PFLIREYJPZDIDR-UHFFFAOYSA-N 0.000 claims description 16
- WBPRDLGEZAEJPK-UHFFFAOYSA-N CCC1=C(O)N2N=CC=C2N=C1C Chemical compound CCC1=C(O)N2N=CC=C2N=C1C WBPRDLGEZAEJPK-UHFFFAOYSA-N 0.000 claims description 16
- AUUVLOAKFBRUDR-UHFFFAOYSA-N 7-chloro-6-ethyl-5-methylpyrazolo[1,5-a]pyrimidine Chemical compound ClC1=C(CC)C(C)=NC2=CC=NN21 AUUVLOAKFBRUDR-UHFFFAOYSA-N 0.000 claims description 15
- QYHQASILWMSICW-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1O Chemical compound CC(C(C)=NC1=CC=NN11)=C1O QYHQASILWMSICW-UHFFFAOYSA-N 0.000 claims description 15
- SWCHOYMUTLUDIK-UHFFFAOYSA-N COC(C=C1)=CC=C1C1=NC2=CC=NN2C(O)=C1 Chemical compound COC(C=C1)=CC=C1C1=NC2=CC=NN2C(O)=C1 SWCHOYMUTLUDIK-UHFFFAOYSA-N 0.000 claims description 15
- 229960000583 acetic acid Drugs 0.000 claims description 15
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- MIRIRTGTSKJYQK-UHFFFAOYSA-N 3-fluoro-4-[5-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxyaniline Chemical compound COC1=CC=C(C=C1)C2=NC3=CC=NN3C(=C2)OC4=C(C=C(C=C4)N)F MIRIRTGTSKJYQK-UHFFFAOYSA-N 0.000 claims description 14
- QMRPRDMCYPYZSQ-UHFFFAOYSA-N 4-(6-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)oxy-3-fluoroaniline Chemical compound CCC1=C(N2C(=CC=N2)N=C1C)OC3=C(C=C(C=C3)N)F QMRPRDMCYPYZSQ-UHFFFAOYSA-N 0.000 claims description 14
- LGJKMBCWZLRACP-UHFFFAOYSA-N 7-chloro-5,6-dimethylpyrazolo[1,5-a]pyrimidine Chemical compound ClC1=C(C)C(C)=NC2=CC=NN21 LGJKMBCWZLRACP-UHFFFAOYSA-N 0.000 claims description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- IOFSBIJFWLMGCL-UHFFFAOYSA-N 7-(2-fluoro-4-nitrophenoxy)-5-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine Chemical compound COC1=CC=C(C=C1)C2=NC3=CC=NN3C(=C2)OC4=C(C=C(C=C4)[N+](=O)[O-])F IOFSBIJFWLMGCL-UHFFFAOYSA-N 0.000 claims description 11
- 230000002194 synthesizing effect Effects 0.000 claims description 11
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 claims description 10
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- PCBCANFQQMWDRR-UHFFFAOYSA-N COC(C=CC(C1=CC=CC(C(N)=O)=N1)=C1)=C1F Chemical compound COC(C=CC(C1=CC=CC(C(N)=O)=N1)=C1)=C1F PCBCANFQQMWDRR-UHFFFAOYSA-N 0.000 claims description 9
- 239000007810 chemical reaction solvent Substances 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 8
- 229910002666 PdCl2 Inorganic materials 0.000 claims description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 8
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 8
- ZFJGKUGPCHVCGY-UHFFFAOYSA-N COC(C=C1)=C(C=O)C=C1C1=CC=CC(C(N)=O)=N1 Chemical compound COC(C=C1)=C(C=O)C=C1C1=CC=CC(C(N)=O)=N1 ZFJGKUGPCHVCGY-UHFFFAOYSA-N 0.000 claims description 7
- 229940093858 ethyl acetoacetate Drugs 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 claims description 5
- OKANYBNORCUPKZ-UHFFFAOYSA-N ethyl 2-ethyl-3-oxobutanoate Chemical compound CCOC(=O)C(CC)C(C)=O OKANYBNORCUPKZ-UHFFFAOYSA-N 0.000 claims description 5
- FNENWZWNOPCZGK-UHFFFAOYSA-N ethyl 2-methyl-3-oxobutanoate Chemical compound CCOC(=O)C(C)C(C)=O FNENWZWNOPCZGK-UHFFFAOYSA-N 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical class [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012263 liquid product Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- KKLCYBZPQDOFQK-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane Chemical class O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1 KKLCYBZPQDOFQK-UHFFFAOYSA-N 0.000 claims description 3
- XURXQNUIGWHWHU-UHFFFAOYSA-N 6-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Br)=N1 XURXQNUIGWHWHU-UHFFFAOYSA-N 0.000 claims description 3
- XOGZMDCWBPWRLX-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(F)=C2OC)=CC=C1)=O)=C1)=C1F Chemical compound CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(F)=C2OC)=CC=C1)=O)=C1)=C1F XOGZMDCWBPWRLX-UHFFFAOYSA-N 0.000 claims description 3
- NOYOBMOMZDYAID-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(OC)=C2OC)=CC=C1)=O)=C1)=C1F Chemical compound CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(OC)=C2OC)=CC=C1)=O)=C1)=C1F NOYOBMOMZDYAID-UHFFFAOYSA-N 0.000 claims description 3
- VQNZFANKAUYKBN-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2F)=CC=C1)=O)=C1)=C1F Chemical compound CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2F)=CC=C1)=O)=C1)=C1F VQNZFANKAUYKBN-UHFFFAOYSA-N 0.000 claims description 3
- LRZCMTOWHIXRMQ-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C2=CC(OC)=CC(OC)=C2)=CC=C1)=O)=C1)=C1F Chemical compound CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C2=CC(OC)=CC(OC)=C2)=CC=C1)=O)=C1)=C1F LRZCMTOWHIXRMQ-UHFFFAOYSA-N 0.000 claims description 3
- NTBMDLFUYYKIDM-UHFFFAOYSA-N CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(OC)=C2OC)=CC=C1)=O)=C1)=C1F Chemical compound CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(OC)=C2OC)=CC=C1)=O)=C1)=C1F NTBMDLFUYYKIDM-UHFFFAOYSA-N 0.000 claims description 3
- OTSDCTPSCKNFTA-UHFFFAOYSA-N CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)=O)=C1)=C1F Chemical compound CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)=O)=C1)=C1F OTSDCTPSCKNFTA-UHFFFAOYSA-N 0.000 claims description 3
- VYSCVRPNTHSRBX-UHFFFAOYSA-N CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C2=CC(OC)=CC(OC)=C2)=CC=C1)=O)=C1)=C1F Chemical compound CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C2=CC(OC)=CC(OC)=C2)=CC=C1)=O)=C1)=C1F VYSCVRPNTHSRBX-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000012964 benzotriazole Substances 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- VRVDABHIWXLTOA-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 VRVDABHIWXLTOA-UHFFFAOYSA-N 0.000 claims description 2
- CXOPUGLYEYDAMC-UHFFFAOYSA-N 6-phenylpyridine-2-carboxylic acid Chemical class OC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 CXOPUGLYEYDAMC-UHFFFAOYSA-N 0.000 claims 1
- ZQTILGDVDYWICD-UHFFFAOYSA-N 6-pyridin-2-ylpyridine-2-carboxylic acid Chemical class OC(=O)C1=CC=CC(C=2N=CC=CC=2)=N1 ZQTILGDVDYWICD-UHFFFAOYSA-N 0.000 claims 1
- STLYPRXQORIBMQ-UHFFFAOYSA-N CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(C=O)=C2OC)=CC=C1)=O)=C1)=C1F Chemical compound CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(C=O)=C2OC)=CC=C1)=O)=C1)=C1F STLYPRXQORIBMQ-UHFFFAOYSA-N 0.000 claims 1
- KYFUSKRSJQABFG-UHFFFAOYSA-N CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(F)=C2OC)=CC=C1)=O)=C1)=C1F Chemical compound CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(F)=C2OC)=CC=C1)=O)=C1)=C1F KYFUSKRSJQABFG-UHFFFAOYSA-N 0.000 claims 1
- PRWAZGHBQFBKOF-UHFFFAOYSA-N CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2F)=CC=C1)=O)=C1)=C1F Chemical compound CCC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2F)=CC=C1)=O)=C1)=C1F PRWAZGHBQFBKOF-UHFFFAOYSA-N 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 154
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 112
- 238000005160 1H NMR spectroscopy Methods 0.000 description 112
- 150000001875 compounds Chemical class 0.000 description 72
- 239000000047 product Substances 0.000 description 62
- 239000007787 solid Substances 0.000 description 57
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 48
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 45
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- WEEVXEKXCIBZMB-UHFFFAOYSA-N 6-(4-fluorophenyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC(F)=CC=2)=N1 WEEVXEKXCIBZMB-UHFFFAOYSA-N 0.000 description 30
- 150000003230 pyrimidines Chemical class 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 238000001308 synthesis method Methods 0.000 description 19
- 238000001035 drying Methods 0.000 description 17
- 125000000714 pyrimidinyl group Chemical group 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- VEKIYFGCEAJDDT-UHFFFAOYSA-N 2-pyridin-3-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1 VEKIYFGCEAJDDT-UHFFFAOYSA-N 0.000 description 12
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- OVJVUDDEZDNPEJ-UHFFFAOYSA-N 6-(3,5-dimethoxyphenyl)pyridine-2-carboxylic acid Chemical compound COC1=CC(OC)=CC(C=2N=C(C=CC=2)C(O)=O)=C1 OVJVUDDEZDNPEJ-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000002390 rotary evaporation Methods 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XGFHPHVJDQZAIJ-UHFFFAOYSA-N 6-(3-formyl-4-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=CC=C2)C(=O)O)C=O XGFHPHVJDQZAIJ-UHFFFAOYSA-N 0.000 description 9
- SBPFRERTSLXOFU-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 SBPFRERTSLXOFU-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- OIOCFHPMDLMALK-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=CC(C(O)=O)=N1 OIOCFHPMDLMALK-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- LVFOPVCLLOCGLW-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CC=CC(C(N)=O)=N2)=C1 Chemical compound COC1=CC(OC)=CC(C2=CC=CC(C(N)=O)=N2)=C1 LVFOPVCLLOCGLW-UHFFFAOYSA-N 0.000 description 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 7
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 7
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 6
- MWWKRDMZEWAKGC-UHFFFAOYSA-N 6-(3-fluoro-4-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=C(F)C(OC)=CC=C1C1=CC=CC(C(O)=O)=N1 MWWKRDMZEWAKGC-UHFFFAOYSA-N 0.000 description 6
- GCJHZLCNAQGOJX-UHFFFAOYSA-N COC(C=CC(C1=CC=CC(C(N)=O)=N1)=C1)=C1OC Chemical compound COC(C=CC(C1=CC=CC(C(N)=O)=N1)=C1)=C1OC GCJHZLCNAQGOJX-UHFFFAOYSA-N 0.000 description 6
- MRGMVAGMXQRFGS-UHFFFAOYSA-N NC(C1=NC(C(C=C2)=CC=C2F)=CC=C1)=O Chemical compound NC(C1=NC(C(C=C2)=CC=C2F)=CC=C1)=O MRGMVAGMXQRFGS-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical class [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- FAMRTHHQYMFCBD-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CC=C(Br)C=C1F FAMRTHHQYMFCBD-UHFFFAOYSA-N 0.000 description 5
- NNDDSRAWMBIROJ-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC=C3OC(F)(F)F)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC=C3OC(F)(F)F)=CC=C2)=O)=C2)=C2F)=C1 NNDDSRAWMBIROJ-UHFFFAOYSA-N 0.000 description 5
- QMNZYBPXUXPHMY-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC=C3OC)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC=C3OC)=CC=C2)=O)=C2)=C2F)=C1 QMNZYBPXUXPHMY-UHFFFAOYSA-N 0.000 description 5
- HGLTWCAKELATSS-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C3=CC(OC)=CC=C3)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C3=CC(OC)=CC=C3)=CC=C2)=O)=C2)=C2F)=C1 HGLTWCAKELATSS-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000004017 serum-free culture medium Substances 0.000 description 5
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VYESPGMXQVOVRN-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(C=O)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(C=O)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 VYESPGMXQVOVRN-UHFFFAOYSA-N 0.000 description 4
- MWHFPLRDFSOYRJ-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC=C3F)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC=C3F)=CC=C2)=O)=C2)=C2F)=C1 MWHFPLRDFSOYRJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229960001701 chloroform Drugs 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- VSMBTFOCAJDGQC-UHFFFAOYSA-N 6-(3-chloro-4-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC=C1C1=CC=CC(C(O)=O)=N1 VSMBTFOCAJDGQC-UHFFFAOYSA-N 0.000 description 3
- UTSGKGBUZVHCBL-UHFFFAOYSA-N 6-(3-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound COC1=CC=CC(C=2N=C(C=CC=2)C(O)=O)=C1 UTSGKGBUZVHCBL-UHFFFAOYSA-N 0.000 description 3
- AKGIUKXMBSFGMN-UHFFFAOYSA-N 6-(4-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=CC(C(O)=O)=N1 AKGIUKXMBSFGMN-UHFFFAOYSA-N 0.000 description 3
- YJXNIEBNJZZIKI-UHFFFAOYSA-N 6-(6-fluoropyridin-3-yl)pyridine-2-carboxylic acid Chemical compound C1=CC(=NC(=C1)C(=O)O)C2=CN=C(C=C2)F YJXNIEBNJZZIKI-UHFFFAOYSA-N 0.000 description 3
- UFJRUWBHVIPTQE-UHFFFAOYSA-N 6-(6-methoxypyridin-3-yl)pyridine-2-carboxylic acid Chemical compound COC1=NC=C(C=C1)C2=NC(=CC=C2)C(=O)O UFJRUWBHVIPTQE-UHFFFAOYSA-N 0.000 description 3
- JBAJBPRCHPGONU-UHFFFAOYSA-N 6-[4-(trifluoromethyl)phenyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC(=CC=2)C(F)(F)F)=N1 JBAJBPRCHPGONU-UHFFFAOYSA-N 0.000 description 3
- OSUDVAVMONWYOK-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(Cl)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(Cl)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 OSUDVAVMONWYOK-UHFFFAOYSA-N 0.000 description 3
- WWBPMRKXSKJOIF-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(F)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(F)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 WWBPMRKXSKJOIF-UHFFFAOYSA-N 0.000 description 3
- OAKLPLFDPCAAGH-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(OC)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C(C=C3)=CC(OC)=C3OC)=CC=C2)=O)=C2)=C2F)=C1 OAKLPLFDPCAAGH-UHFFFAOYSA-N 0.000 description 3
- DHZJFNGIVREZPK-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C3=CC(OC)=CC(OC)=C3)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C3=CC(OC)=CC(OC)=C3)=CC=C2)=O)=C2)=C2F)=C1 DHZJFNGIVREZPK-UHFFFAOYSA-N 0.000 description 3
- BIVQXXHLPYNXLD-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C3=CC=C(C(F)(F)F)C=C3)=CC=C2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=NC(C3=CC=C(C(F)(F)F)C=C3)=CC=C2)=O)=C2)=C2F)=C1 BIVQXXHLPYNXLD-UHFFFAOYSA-N 0.000 description 3
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- XGVAEAVGTOZSNS-UHFFFAOYSA-N 1-[(4-methoxyphenoxy)methyl]-4-nitrobenzene Chemical compound C1=CC(OC)=CC=C1OCC1=CC=C([N+]([O-])=O)C=C1 XGVAEAVGTOZSNS-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- IWZVHUTZMULWDQ-UHFFFAOYSA-N 6-(4-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=C(F)C(OC)=CC(C=2N=C(C=CC=2)C(O)=O)=C1 IWZVHUTZMULWDQ-UHFFFAOYSA-N 0.000 description 2
- PMOHFTPTTDTFIS-UHFFFAOYSA-N 6-[4-(trifluoromethyl)phenyl]pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(C=2C=CC(=CC=2)C(F)(F)F)=N1 PMOHFTPTTDTFIS-UHFFFAOYSA-N 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 102000052609 BRCA2 Human genes 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- JOAJOABCZFMTPN-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(C=O)=C2OC)=CC=C1)=O)=C1)=C1F Chemical compound CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC(C=O)=C2OC)=CC=C1)=O)=C1)=C1F JOAJOABCZFMTPN-UHFFFAOYSA-N 0.000 description 2
- NKSFJQYIWHEJBK-UHFFFAOYSA-N CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)=O)=C1)=C1F Chemical compound CC(C(C)=NC1=CC=NN11)=C1OC(C=CC(NC(C1=NC(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)=O)=C1)=C1F NKSFJQYIWHEJBK-UHFFFAOYSA-N 0.000 description 2
- FEGORILNRABRDZ-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=CC=CC(C(C=N3)=CC=C3F)=N2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=CC=CC(C(C=N3)=CC=C3F)=N2)=O)=C2)=C2F)=C1 FEGORILNRABRDZ-UHFFFAOYSA-N 0.000 description 2
- AAJAPNGXRBVXTL-UHFFFAOYSA-N CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=CC=CC(C(C=N3)=CC=C3OC)=N2)=O)=C2)=C2F)=C1 Chemical compound CC1=NC2=CC=NN2C(OC(C=CC(NC(C2=CC=CC(C(C=N3)=CC=C3OC)=N2)=O)=C2)=C2F)=C1 AAJAPNGXRBVXTL-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- XUIURRYWQBBCCK-UHFFFAOYSA-N (3,5-dimethoxyphenyl)boronic acid Chemical compound COC1=CC(OC)=CC(B(O)O)=C1 XUIURRYWQBBCCK-UHFFFAOYSA-N 0.000 description 1
- VUTJHOWRPUPHIG-UHFFFAOYSA-N (3-chloro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1Cl VUTJHOWRPUPHIG-UHFFFAOYSA-N 0.000 description 1
- IILGLPAJXQMKGQ-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1F IILGLPAJXQMKGQ-UHFFFAOYSA-N 0.000 description 1
- YJQDBKGGRPJSOI-UHFFFAOYSA-N (3-formyl-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1C=O YJQDBKGGRPJSOI-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- OJBYZWHAPXIJID-UHFFFAOYSA-N (6-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(F)N=C1 OJBYZWHAPXIJID-UHFFFAOYSA-N 0.000 description 1
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- VNBUMBNLPGLBML-UHFFFAOYSA-N 8-methoxy-9-methylfuro[2,3-b]quinolin-4-one Chemical compound COC1=CC=CC(C2=O)=C1N(C)C1=C2C=CO1 VNBUMBNLPGLBML-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- UQUNLHARCWNAEX-UHFFFAOYSA-N COC(C=CC(C1=CC=CC(C(N)=O)=N1)=C1)=C1Cl Chemical compound COC(C=CC(C1=CC=CC(C(N)=O)=N1)=C1)=C1Cl UQUNLHARCWNAEX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910004057 NO2F Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- IXMQSJMHAYPXSV-UHFFFAOYSA-N n-[(4-nitrophenyl)methylideneamino]aniline Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=NNC1=CC=CC=C1 IXMQSJMHAYPXSV-UHFFFAOYSA-N 0.000 description 1
- GCCOCVPSHOAIKC-UHFFFAOYSA-N n-methyl-n-phenyldiazenylacetamide Chemical compound CC(=O)N(C)N=NC1=CC=CC=C1 GCCOCVPSHOAIKC-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pyridine amide compound, which has a structural general formula shown in formulas (I) and (II). The invention also discloses a preparation method of the pyridine amide compound and application of the pyridine amide compound in preparing antitumor drugs.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a pyridine amide compound, and a preparation method and application thereof.
Background
c-Met is a receptor for Hepatocyte Growth Factor (HGF), and when HGF binds to the receptor c-Met, cell signaling is widely transmitted, including involvement in cell proliferation, motility, migration and invasion. The abnormally conducted HGF/c-Met signal is a driving factor of various malignant tumors and can promote the growth, invasion, propagation and angiogenesis of tumors. The poor clinical treatment effect of some medicines and the drug resistance of approved targeted therapeutic medicines are related to the abnormal HGF/c-Met signal.
The PARP-1 inhibitor can affect the self-replication mode of cancer cells, inhibit the DNA damage repair of the cancer cells and promote the apoptosis of the cancer cells, thereby enhancing the curative effects of radiotherapy and alkylating agent and platinum drug chemotherapy, and being used for treating advanced ovarian cancer patients with BRCA1 and BRCA2 germline mutations and treating BRCA2 HER2 negative metastatic breast cancer. Besides breast cancer, the medicine can also treat hereditary cancers such as ovarian cancer, prostatic cancer, pancreatic cancer and the like which have the same 'rogue gene'. Unfortunately, clinically used PARP inhibitors also present the problem of drug resistance.
It has been found that the combined use of c-Met and PARP-1 inhibitors synergistically prevents the growth of breast cancer cells. Moreover, the combination has similar effect in a lung cancer model of a mouse. For those patients with high c-Met expression and at the same time a PARP-1 inhibitor insensitivity, it may be possible to benefit from the combined use of c-Met and PARP-1 inhibitors, and such combined treatment may have an effect on a wide variety of tumors of this type. In this context, dual-target inhibitors that selectively target c-Met and PARP-1 are new hopes for being explored as tumor patients.
Disclosure of Invention
The invention aims to provide a pyridine amide compound which can effectively inhibit tumors caused by HGF/c-Met and PARP related signal channel abnormality, has good antitumor activity and can be used for preparing antitumor drugs; the invention also aims to provide a preparation method and medical application of the pyridine amide compound.
In order to realize the purpose, the invention adopts the technical scheme that:
a pyridine amide compound has a structural general formula shown in formulas (I) and (II):
wherein:
R1and R2Are independently selected from hydrogen, methyl, ethyl, halo, phenyl, benzyl, pyrimidinyl, pyridinyl, pyrazinyl, halo-substituted phenyl, methoxy-substituted pyrimidinyl, methoxy-substituted pyrazinyl, methoxy-and halo-substituted phenyl, methoxy-and halo-substituted pyrimidinyl, methoxy-and halo-substituted pyridinyl, or methoxy-and halo-substituted pyrazinyl;
R3selected from methyl, ethyl, halogen, methoxy, trifluoromethoxy, or trifluoromethyl.
Preferably, the halogen in the halogen and the halogen substituted phenyl is selected from F, Cl or Br, respectively.
Preferably, the picolinamide compound is selected from the group consisting of 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-picolinamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-picolinamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-chloro-4-methoxyphenyl) -2-picolinamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethylphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6' -methoxy- [2,3' -bipyridine ] -6-carboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6' -fluoro- [2,3' -bipyridine ] -6-carboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, a salt thereof, a mixture thereof, and a pharmaceutically acceptable carrier, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine -picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamidophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridinecarboxamidophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) - 2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine.
Preferably, the picolinamide compound is selected from the group consisting of 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine.
The pyridine amide compound is synthesized by performing chlorination reaction, ether forming reaction, reduction reaction and amide forming reaction on a pyrazolo [1,5-a ] pyrimidine derivative.
The synthetic raw materials of the pyrazolo [1,5-a ] pyrimidine derivative comprise 3-aminopyrazole and an ethyl acetoacetate derivative. Preferably, the ethyl acetoacetate derivative comprises at least one of ethyl acetoacetate, ethyl 2-methylacetoacetate, ethyl 2-ethylacetoacetate and ethyl 4-methoxybenzoyl acetate.
The pyrazolo [1,5-a ] pyrimidine derivative includes at least one of 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, and 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine.
The invention also provides a preparation method of the pyridine amide compound, which comprises the following steps:
(1) synthesis of intermediates 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine:
taking 3-aminopyrazole and ethyl acetoacetate or ethyl 2-methylacetoacetate or ethyl 2-ethylacetoacetate, adding glacial acetic acid as a reaction solvent, heating and stirring for reaction, and separating and purifying after the reaction is finished to obtain solid products, namely the 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine;
(2) synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine:
taking 4-methoxybenzoyl ethyl acetate and 3-aminopyrazole, adding acetic acid as a reaction solvent, carrying out reflux reaction, and separating and purifying after the reaction is finished to obtain a solid product, namely the 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine;
(3) synthesis of intermediates 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, or 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine:
taking 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, N-dimethylaniline or diethylamine or triethylamine and phosphorus oxychloride, reacting for 24-48 h at 20-60 ℃, slowly pouring the reaction system into ice water while stirring under the ice bath condition, adjusting the pH value to be neutral after recovering the normal temperature, separating and purifying to obtain oily liquid products, namely the 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine and 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, or 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine;
or taking 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine and phosphorus oxychloride, carrying out reflux reaction for 4-8 h at 110-130 ℃, slowly pouring a reaction system into ice water while stirring under an ice bath condition, recovering to normal temperature, and carrying out separation and purification to obtain a solid product, namely the 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine;
(4) synthesis of intermediates 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine:
dissolving 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine in chlorobenzene or toluene or xylene, adding 2-fluoro-4-nitrophenol, heating, stirring, reacting, separating and purifying to obtain a solid product, namely the 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine;
(5) synthesis of intermediates 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, or 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine:
adding acetic acid solution or formic acid solution or ammonium chloride solution, and 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine into reduced iron powder, separating and purifying after the reaction is finished, the obtained solid product is the 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, or 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine;
(6) synthesis of intermediate 6- (phenyl or pyridyl) -2-pyridinecarboxylic acid Compounds:
taking 2-bromo-6-pyridinecarboxylic acid, substituted phenylboronic acid or phenylboronic acid pinacol ester, cesium carbonate and Pd (PPh)3)4Or PdCl2Or PdCl2(dppf) or Pd (OAc)2Or Pd (PPh)3)2Cl2Carrying out reflux reaction under the protection of nitrogen, and separating and purifying after the reaction is finished to obtain a solid product, namely the 6- (phenyl or pyridyl) -2-pyridine carboxylic acid compound; (Note: Pd (PPh)3)4The Chinese name of (A) is "tetrakis (triphenylphosphine) palladium"; PdCl2Is named as "palladium chloride"; PdCl2(dppf) referred to herein as "1, 1' -bis-diphenylphosphinoferrocene palladium dichloride"; pd (OAc)2Is named as "palladium acetate"; pd (PPh)3)2Cl2The Chinese name of (1) is "bis (triphenylphosphine) palladium (II) chloride")
(7) Synthesizing the pyridine amide compound:
taking 6- (phenyl or pyridyl) -2-pyridine carboxylic acid compounds, 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethylurea Hexafluorophosphate (HATU), N, N-Diisopropylethylamine (DIPEA), and 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4- And (2) reacting the amino phenoxy) -pyrazolo [1,5-a ] pyrimidine at 0-60 ℃ for 8-25 h, and separating and purifying after the reaction is finished to obtain a solid product, namely the pyridine amide compound.
In some embodiments, in step (1), the ratio of 3-aminopyrazole: ethyl acetoacetate, ethyl 2-methylacetoacetate or ethyl 2-ethylacetoacetate (1-1.2): 1; the conditions of the heating stirring reaction are as follows: stirring and reacting for 1-3 h at 100-140 ℃, preferably stirring and reacting for 1.5h at 120 ℃.
In some embodiments, in step (2), the molar ratio of ethyl 4-methoxybenzoylacetate: 3-aminopyrazole ═ 1: 1; the conditions of the reflux reaction are as follows: reflux reaction is carried out for 4-8 h at 110-130 ℃, and preferably for 6h at 120 ℃.
In some embodiments, in step (3), 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, in terms of mole ratios: n, N-dimethylaniline or diethylamine or triethylamine: 1, (3-5) and (6-10) of phosphorus oxychloride.
In some embodiments, in step (3), 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, in terms of mole ratios: n, N-dimethylaniline or diethylamine or triethylamine: phosphorus oxychloride (1: 4: 8).
In some embodiments, in step (3), when the 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, or 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine is prepared: adding sodium hydroxide or potassium hydroxide or ammonia water solution to adjust the pH value to be neutral; the separation and purification comprises filtering, extracting the filtrate with dichloromethane or trichloromethane, drying the extract with anhydrous sodium sulfate, filtering, rotary-steaming the filtrate to obtain purple black aqueous liquid, and purifying with silica gel column chromatography to obtain oily liquid product.
In some embodiments, in step (3), when the 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine is prepared: the separation and purification comprises extracting with dichloromethane or trichloromethane, drying the extract with anhydrous sodium sulfate, filtering, concentrating the filtrate by rotary evaporation, and purifying with silica gel column chromatography to obtain solid product.
In some embodiments, in step (4), the 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine: 2-fluoro-4-nitrophenol (3.5 to 7.5): 4.5 to 8.5); the conditions of the heating stirring reaction are as follows: reacting for 1-10 h at 100-130 ℃.
When the 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine is prepared, carbonate is added into chlorobenzene or toluene or xylene; preferably, the carbonate is potassium carbonate.
In some embodiments, in step (5), the ratio of reduced iron powder: 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine ═ 1 (2-4): 1.
In some embodiments, in step (5), the ratio of reduced iron powder: 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine ═ 3: 1.
In some examples, in the step (5), the reduced iron powder is mixed with an acetic acid solution or a formic acid solution or an ammonium chloride solution, heated and stirred, activated at 90 ℃ for 1-1.5 h, and then added with 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine reacts for 3-8 h at 80-100 ℃, after the reaction is finished, the filtration is carried out, acetone or ethyl acetate or n-butyl alcohol is used for extracting filtrate, anhydrous sodium sulfate is used for drying extract liquor, rotary evaporation is carried out to remove solvent, and the solid product is obtained after silica gel column chromatography purification.
In some embodiments, in step (6), the ratio, in terms of mole ratios, of 2-bromo-6-pyridinecarboxylic acid: substituted phenylboronic acid or phenylboronic acid pinacol ester: cesium carbonate: pd (PPh)3)4Or PdCl2Or PdCl2(dppf) or Pd (OAc)2Or Pd (PPh)3)2Cl22.458:2.048:4.097: 0.0819; the substituted phenylboronic acid is preferably 4-fluorobenzeneboronic acid; the conditions of the reflux reaction are as follows: carrying out reflux reaction at 70-110 ℃ for 1-6 h, preferably at 90 ℃ for 3 h; the reaction solvent of the reflux reaction is a mixed solution of toluene and ethanol; the separation step after the completion of the reflux reaction comprises: removing the solvent by rotary evaporation, redissolving the solid by water, extracting by acetone or ethyl acetate or n-butyl alcohol, removing the organic phase, adjusting the pH of the water phase to 3-5 by hydrochloric acid or acetic acid or formic acid, extracting by acetone or ethyl acetate or n-butyl alcohol, collecting the organic phase, drying, and carrying out rotary evaporation and concentration to obtain a solid product.
In some embodiments, in step (7), the 6- (phenyl or pyridyl) -2-pyridinecarboxylic acid compound is HATU: DIPEA: 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine (0.5-1.0) to (0.5-1.0):
(0.9~1.7):(0.5~0.8)。
in some embodiments, in step (7), the reaction solvent of the reaction is DCM or dichloromethane, and the isolation comprises: washing the organic phase with saturated sodium chloride solution for three times, washing off reaction by-products, drying the organic phase with anhydrous sodium sulfate, filtering to obtain a crude product, and purifying the crude product; or adjusting the pH to 6-7 by using a saturated sodium bicarbonate solution, extracting by using dichloromethane, drying the extract by using anhydrous sodium sulfate, filtering, and purifying the filtrate.
Preferably, in the preparation method of the pyridine amide compound, petroleum ether and ethyl acetate are used as eluent when the pyridine amide compound passes through a chromatographic column.
The invention also provides a synthesis method of the 4-methoxybenzoyl ethyl acetate, which comprises the following steps: taking diethyl carbonate, cooling to 0 ℃, adding sodium hydride or potassium hydroxide or ammonia, stirring uniformly, adding 4' -methoxyacetophenone, reacting for 1-2 h, adding an acid solution, reacting for 1-2 h at normal temperature, extracting with ethyl acetate or dichloromethane or trichloromethane, drying, filtering, and performing rotary evaporation to obtain an oily liquid product, namely the 4-methoxybenzoyl ethyl acetate.
In some embodiments, in the method for synthesizing ethyl 4-methoxybenzoyl acetate, the molar ratio of diethyl carbonate: sodium or potassium hydroxide or ammonia: 4' -methoxyacetophenone ═ 2.5:3.5: 1.
In some embodiments, in the method for synthesizing ethyl 4-methoxybenzoyl acetate, the acidic solution is selected from one of hydrochloric acid, formic acid and acetic acid, and preferably acetic acid.
In some embodiments, in the method of synthesizing ethyl 4-methoxybenzoyl acetate, the extraction is performed as a reaction product: 1-extractant: 1, adding ethyl acetate or dichloromethane or trichloromethane, and extracting for three times.
The synthetic route of the pyridine amide compound is as follows:
the invention also provides application of the pyridine amide compound in preparation of antitumor drugs.
The pyridine amide compound provided by the invention has good anti-tumor activity and can be used for preparing anti-tumor drugs.
Preferably, the tumor is caused by an abnormality in HGF/c-Met and PARP-associated signaling pathways.
Preferably, the tumor comprises human breast cancer, human lung cancer, human liver cancer and human neuroblastoma.
The invention also provides an anti-tumor medicament which contains the pyridine amide compound and a pharmaceutically acceptable carrier.
Preferably, the dosage forms of the anti-tumor drug comprise injection dosage forms and oral dosage forms.
Preferably, the injection preparation comprises injection and freeze-dried powder.
Preferably, the oral dosage forms include tablets, granules, capsules, powders and solutions.
Compared with the prior art, the invention has the beneficial effects that: (1) the preparation method takes 3-aminopyrazole and ethyl acetoacetate derivatives as raw materials, synthesizes intermediate pyrazolo [1,5-a ] pyrimidine derivatives, synthesizes a series of pyridine amide compounds with anti-tumor activity for the first time through chlorination, ether formation, reduction and amide formation reactions, and confirms the structure of the pyridine amide compounds through high-resolution mass spectrometry, nuclear magnetic resonance hydrogen spectrum and carbon spectrum; (2) the test of in vitro tumor cell inhibition activity shows that the pyridine amide compounds have good inhibition effect on tumor cells such as human breast cancer cells MDA-MB-231, human breast cancer cells MCF-7, human lung adenocarcinoma cells A549 and human liver cancer cells Hep G2 (IC 50: 0.1-100 mu M), have anti-tumor activity and can be used for preparing anti-tumor drugs; (3) the growth test of the xenograft tumor in the body of the mouse shows that the pyridine amide compound has good tumor inhibiting effect and can be used for treating the tumor; (4) the pyridine amide compound has the effect of inhibiting or killing tumor cells, and can be used for preparing antitumor drugs for treating human breast cancer, human lung cancer and human liver cancer; (5) the method for preparing the pyridine amide compound has the advantages of simple operation process, short synthetic route, low cost and the like.
Drawings
FIG. 1 shows 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy group]-5-methylpyrazolo [1,5-a]Process for preparing pyrimidines1A HNMR map;
FIG. 2 shows 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy group]-a 5-methylpyrazolo [1,5-a]process for preparing pyrimidines13A C NMR spectrum;
FIG. 3 is an HR-MS-ESI spectrum of 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention is further illustrated by the following examples. It is apparent that the following examples are only a part of the embodiments of the present invention, and not all of them. It should be understood that the embodiments of the present invention are only for illustrating the technical effects of the present invention, and are not intended to limit the scope of the present invention.
The embodiment of the invention provides a pyridine amide compound, which has the structural general formulas shown as the following formula (I) and (II):
the pyridine amide compound is selected from 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine carboxamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine carboxamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-chloro-4-methoxyphenyl) -2-pyridine carboxamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethylphenyl) -2-pyridine carboxamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine -picolinamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6' -methoxy- [2,3' -bipyridine ] -6-carboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6' -fluoro- [2,3' -bipyridine ] -6-carboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, a salt thereof, a mixture thereof, and a pharmaceutically acceptable carrier, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine -picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamidophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridinecarboxamidophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) - 2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine.
The preparation methods of the thirty picolinamide compounds are shown in examples 1-30. The following examples are only some examples of the present invention, and should not be construed as limiting the scope of the present invention. The target products can be obtained by other conditions in the preparation method of the pyridine amides of the invention, which are not specifically exemplified herein for reasons of space.
Example 1
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine carboxamide) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3Methyl, R2Is H, R3Is 4-F, and the compound number is GMZC-Q-1.
The preparation method of the compound GMZC-Q-1 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine
Weighing 4.860g (58.000mmol) of 3-aminopyrazole and 7.541g (58.000mmol) of ethyl acetoacetate, adding into a round-bottom flask, adding 20mL of glacial acetic acid as a reaction solvent, heating and stirring, reacting at 120 ℃ for 1.5h, and detecting by TLC; after the reaction is finished, cooling, suction filtration and washing of the upper-layer precipitate with absolute ethyl alcohol are carried out to obtain 6.103g of white solid which is the intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI shown below), yield 70%;
1H NMR(400MHz,DMSO-d6)δ12.28(s,1H),7.82(t,J=2.4Hz,1H),6.11~6.03(m,1H),5.59~5.52(m,1H),2.28(d,J=0.6Hz,3H);
13C NMR(101MHz,DMSO-d6)δ156.83,150.70,143.14,142.12,95.36,88.74,19.10;
HR-ESI-MS Calcd.for C7H7N3O[M+H]+:150.06619;found:150.06609。
(2) synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine
Weighing 5-methyl-7-hydroxy-pyrazolo [1,5-a ]]2.500g (16.800mmol) of pyrimidine is added into a round-bottom flask, 8.450mL (67.100mmol) of N, N-dimethylaniline and 12.25mL (134.400mmol) of phosphorus oxychloride are added in sequence, stirred, reacted at 35 ℃ for 36h, and detected by TLC; after the reaction is finished, slowly pouring the reaction system into a beaker filled with 100mL of ice water while stirring under the ice bath condition, quenching phosphorus oxychloride, adding a sodium hydroxide solution to adjust the pH to be neutral after the reaction system is recovered to the normal temperature, filtering, extracting the filtrate for three times by using DCM (100 mL each time), drying the extract by using anhydrous sodium sulfate, filtering, carrying out rotary evaporation on the filtrate to obtain a purple black aqueous liquid, and purifying by silica gel column chromatography (taking ethyl acetate and petroleum ether as eluent, and taking the ethyl acetate and the petroleum ether (V: V) ═ 1: 12)]To obtain 2.013g of a transparent oily liquid, which was an intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI shown below), yield 70%;
1H NMR(400MHz,CDCl3)δ7.97(t,J=3.3Hz,1H),6.64(s,1H),6.46(d,J=2.3Hz,1H),2.39(d,J=3.4Hz,3H);
13C NMR(101MHz,CDCl3)δ158.37,149.39,145.22,138.11,108.75,97.24,24.52;
HR-ESI-MS Calcd.for C7H6N3Cl[M+H]+:168.03230;found:168.03207。
(3) synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine
Weighing 5-methyl-7-chloro-pyrazolo [1,5-a ]]Adding 1.210g (7.100mmol) of pyrimidine into a round-bottom flask, adding 2mL of chlorobenzene for dissolving, pouring 1.354g (8.500mmol) of 2-fluoro-4-nitrophenol, heating and stirring, and reacting at 110 ℃ for 2 hours; after the reaction is finished, rotary evaporation is carried out, and the mixture is purified by silica gel column chromatography (ethyl acetate and petroleum ether are used as eluent, and the ratio of ethyl acetate to petroleum ether (V: V) is 1: 10]To obtain 1.030g of yellow-green solid which is the intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI shown below), yield 50%;
1H NMR(400MHz,CDCl3)δ8.22~8.15(m,2H),8.13(d,J=2.2Hz,1H),7.52~7.46(m,1H),6.64~6.60(m,1H),5.90(s,1H),2.52(d,J=0.5Hz,3H);
13C NMR(101MHz,CDCl3)δ160.56,154.56,151.99,150.76,145.97,144.72,123.37,121.07,114.26,114.03,96.56,90.71,25.20;
HR-ESI-MS Calcd.for C13H9N4O3F[M+H]+:289.07214;foun d:289.07263。
(4) synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine
0.588g (10.500mmol) of reduced iron powder is weighed, added into a round-bottom flask containing 20mL of acetic acid solution with the pH value of 2-3, heated and stirred, activated at 90 ℃ for 1h, and added with 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine 1.008g (3.500mmol) and reacting at 90 ℃ for 5 h; after the reaction, the mixture is filtered while the reaction is still hot, the filtrate is extracted with ethyl acetate for three times, 50mL each time, the upper layer is taken, dried by anhydrous sodium sulfate, the solvent is removed by rotary evaporation, and the mixture is purified by silica gel column chromatography (taking ethyl acetate and petroleum ether as eluent, and the ratio of ethyl acetate to petroleum ether (V: V) is 1: 8]Obtaining 0.650g of white solid, namely the intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI shown below), yield 72%;
1H NMR(400MHz,DMSO-d6)δ9.96(s,1H),9.60(s,1H),8.08(d,J=2.2Hz,1H),7.25(dd,J=12.3,2.4Hz,1H),7.06(ddd,J=28.4,10.3,4.6Hz,2H),6.35(d,J=2.2Hz,1H),6.03(s,1H),2.34(s,3H);
13C NMR(101MHz,DMSO-d6)δ159.47,152.43,150.03,149.43,145.87,143.93,129.11,121.96,118.49,113.96,94.36,86.61,25.04;
HR-ESI-MS Calcd.for C13H11N4OF[M+H]+:259.09897;found:259.09827。
(5) synthesis of intermediate 6- (4-fluorophenyl) -2-pyridinecarboxylic acid
Weighing 2-bromo-60.5g (2.458mmol) of pyridine carboxylic acid, 0.287g (2.048mmol) of 4-fluorobenzeneboronic acid, 1.335g (4.097mmol) of cesium carbonate and 0.095g (0.0819mmol) of tetrakis (triphenylphosphine) palladium are added into a two-neck round-bottom flask in sequence, vacuum pumping is carried out in a sealed manner, nitrogen is introduced for protection, 30mL of a reaction solvent (the reaction solvent consists of toluene and ethanol, and the ratio of toluene to ethanol (V: V) is 1: 1) is added by a syringe, and reflux reaction is carried out for 3 hours at 90 ℃; after the reaction is finished, the solvent is removed by rotary evaporation, the solid is re-dissolved by distilled water, the ethyl acetate is used for extraction once, and the organic phase is discarded. Adjusting the pH value of the water phase to 4 by using a dilute hydrochloric acid solution, extracting the water phase by using ethyl acetate for three times, collecting an organic phase, drying by using anhydrous sodium sulfate, and performing spin drying to obtain a light yellow solid, namely an intermediate 6- (4-fluorophenyl) -2-pyridinecarboxylic acid (0.356 g)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 80%;
1H NMR(400MHz,CDCl3)δ8.20~8.15(m,1H),8.05~8.01(m,1H),8.01~7.99(m,1H),7.99~7.97(m,1H),7.97~7.94(m,1H),7.24~7.21(m,1H),7.21~7.17(m,1H);
13C NMR(101MHz,CDCl3)δ165.42,164.20,162.93,155.61,146.00,139.51,133.32,129.09,124.62,122.04,116.33,116.11;
HR-ESI-MS Calcd.for C12H8NO2F[M+H]+:218.06126;foun d:218.06116。
(6) synthesis of the product 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine
0.171g (0.788mmol) of 6- (4-fluorophenyl) -2-pyridinecarboxylic acid and 0.300g (0.788mmol) of 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HATU) were put in a round-bottomed flask, dissolved in 8mL of DCM, stirred for 10min, then added with 0.239mL (1.444mmol) of N, N-Diisopropylethylamine (DIPEA), stirred for 10min, slowly added dropwise with 10mL of 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] containing]0.169g (0.657mmol) of pyrimidine in DCM for 10min, reacting the system at 30 ℃ for 12h, and detecting by thin layer chromatography; washing the organic phase with saturated sodium chloride solution for three times after the reaction is finished, washing off reaction by-products, and drying with anhydrous sodium sulfateDrying the organic phase, filtering to obtain crude product, and purifying with silica gel column chromatography [ using ethyl acetate and petroleum ether as eluent, and ethyl acetate/petroleum ether (V: V) ═ 1: 6]Obtaining 0.146g of white solid, namely the product 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI spectra shown in FIG. 1, FIG. 2 and FIG. 3, respectively), yield was 49%;
1H NMR(400MHz,CDCl3)δ8.21(dd,J=6.5,1.9Hz,1H),8.12(d,J=5.4Hz,1H),8.10(d,J=5.4Hz,1H),8.01(d,J=2.2Hz,1H),7.98(s,1H),7.96~7.93(m,1H),7.42(t,J=8.4Hz,1H),7.29(dd,J=10.7,2.4Hz,1H),7.22(dd,J=5.3,4.1Hz,1H),7.18(s,1H),7.16(s,1H),6.49(d,J=2.2Hz,1H),6.30(s,1H),2.53(s,3H);
13C NMR(101MHz,CDCl3)δ165.30,163.03,159.98,157.11,148.93,146.59,143.96,143.85,138.13,136.30,135.85,134.35,129.27,129.19,125.01,124.34,124.11,119.40,116.10,115.88,112.24,112.02,95.55,87.00,25.29;
HR-ESI-MS Calcd.for C25H17N5O2F2[M+H]+:458.14139;found:458.14176。
example 2
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 3-F and 4-OCH3The compound is numbered as GMZC-Q-2.
The preparation method of the compound GMZC-Q-2 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxylic acid: the synthesis method is similar to step (5) of example 1, except that this step replaces 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 3-fluoro-4-methoxybenzeneboronic acid, and the rest of the conditions are unchanged. Finally obtaining 0.412g of light yellow solid which is the intermediate 6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxylic acid (b)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 81%.
1H NMR(400MHz,CDCl3)δ8.13(d,J=8.3Hz,1H),8.03~7.96(m,1H),7.92(d,J=8.6Hz,1H),7.76(s,1H),7.73(s,1H),7.08(t,J=8.6Hz,1H),3.96(s,3H);
13C NMR(101MHz,CDCl3)δ164.24,155.09,153.94,151.48,145.91,139.44,132.65,124.17,123.12,121.84,114.81,113.52,56.41;
HR-ESI-MS Calcd.for C13H10NO3F[M+H]+:248.07183;found:248.07175。
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally obtaining 0.160g of white solid, namely the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 50%.
1H NMR(400MHz,DMSO-d6)δ9.96(d,J=26.7Hz,1H),8.29(dd,J=7.6,1.3Hz,1H),8.15(dd,J=7.7,1.3Hz,1H),8.12(d,J=7.8Hz,1H),8.11~8.08(m,1H),8.05~8.01(m,1H),7.99(dt,J=4.5,2.3Hz,1H),7.59(dt,J=8.6,3.4Hz,1H),7.56~7.53(m,1H),7.41(d,J=8.6Hz,1H),7.29(dd,J=10.9,7.0Hz,1H),6.39(d,J=2.2Hz,1H),6.37(s,1H),3.88(s,3H),2.36(d,J=11.9Hz,3H).
13C NMR(101MHz,DMSO-d6)δ163.12,159.78,155.76,152.74,151.06,149.50,149.07,146.22,144.59,144.03,139.55,137.50,135.06,132.06,130.95,129.21,125.22,124.80,123.93,120.55,114.51,112.53,94.78,87.60,56.68,25.14.
HR-ESIMS Calcd.for C26H19N5O3F2[M+H]+:488.15295;found:488.15239。
Example 3
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-chloro-4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 3-Cl and 4-OCH3The compound is numbered as GMZC-Q-3.
The preparation method of the compound GMZC-Q-3 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (3-chloro-4-methoxyphenyl) -2-pyridinecarboxylic acid: the synthesis was similar to step (5) of example 1, except that this step replaced 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 3-chloro-4-methoxybenzeneboronic acid, and the rest of the conditions were unchanged. Finally obtaining 0.487g of light yellow solid which is the intermediate 6- (3-chloro-4-methoxyphenyl) -2-pyridinecarboxylic acid (1H NMR、13C NMR and HR-MS-ESI are shown below), yield 90%.
1H NMR(400MHz,CDCl3)δ8.14(d,J=8.5Hz,1H),8.02(s,1H),7.99(d,J=7.5Hz,1H),7.92(d,J=7.9Hz,1H),7.88(d,J=10.3Hz,1H),7.05(d,J=8.6Hz,1H),3.98(s,3H).
13C NMR(101MHz,CDCl3)δ164.17,156.65,154.98,145.92,139.46,130.38,128.88,126.58,124.19,123.43,121.84,112.26,56.43.
HR-ESI-MSCalcd.forC13H10NO3Cl[M+H]+:264.04228;found:264.04208.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-chloro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3-chloro-4-methoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally, 0.173g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 52%.
1H NMR(400MHz,DMSO-d6)δ9.99(s,1H),8.32(dd,J=7.7,1.3Hz,1H),8.24(d,J=2.2Hz,1H),8.16(dd,J=7.6,1.2Hz,1H),8.13(dd,J=5.6,2.2Hz,1H),8.12~8.11(m,1H),8.10(d,J=2.8Hz,1H),7.59~7.57(m,1H),7.57~7.54(m,1H),7.45~7.38(m,1H),7.30~7.25(m,1H),6.38(t,J=2.3Hz,1H),6.37(s,1H),3.90(d,J=4.9Hz,3H),2.38(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.13,159.79,156.35,155.59,152.74,149.51,146.23,144.60,144.05,139.60,135.06,131.96,131.30,129.22,128.60,127.49,125.25,124.85,122.27,120.59,113.58,94.78,87.59,86.59,56.89,25.14.
HR-ESI-MS Calcd.for C26H19N5O3FCl[M+H]+:504.12340;found:504.12301.
Example 4
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-trifluoromethylphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine belonging to the genus of knotGeneral formula (I), R1Is CH3,R2Is H, R3Is 4-CF3The compound is numbered as GMZC-Q-4.
The preparation method of the compound GMZC-Q-4 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (4-trifluoromethylphenyl) -2-pyridinecarboxylic acid: the synthesis method is similar to step (5) of example 1, except that this step replaces 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 4-trifluoromethylphenylboronic acid, and the rest of the conditions are unchanged. Finally obtaining 0.466g of light yellow solid, namely the intermediate 6- (4-trifluoromethylphenyl) -2-pyridinecarboxylic acid (b)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 85%.
1H NMR(400MHz,DMSO-d6)δ8.41(d,J=7.1Hz,1H),8.39(s,1H),8.30(s,1H),8.16~8.09(m,1H),8.08(s,1H),7.90(d,J=2.9Hz,1H),7.87(s,1H).
13C NMR(101MHz,DMSO-D6)δ166.54,154.86,149.01,142.07,139.48,130.26,129.95,128.15,128.15,126.26,124.68,124.56,123.41.
HR-ESI-MSCalcd.forC13H8NO2F3[M+H]+:268.05707;found:268.05794.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-trifluoromethylphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -one-carboxylic acid of example 1 with an equimolar amount of 6- (4-trifluoromethylphenyl) -2-pyridinecarboxylic acid2-pyridine carboxylic acid, and the rest conditions are unchanged. Finally, 0.189g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (4-trifluoromethylphenyl) -2-pyridine carboxamide) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 56%.
1H NMR(400MHz,DMSO-d6)δ10.03(s,1H),8.46(dd,J=7.8,1.0Hz,1H),8.42(s,1H),8.40(s,1H),8.31(dd,J=7.7,1.0Hz,1H),8.26(t,J=7.8Hz,1H),8.15(d,J=2.2Hz,1H),7.93(s,1H),7.92~7.89(m,1H),7.63(dd,J=10.8,7.9Hz,1H),7.59(d,J=8.7Hz,1H),7.46(d,J=8.7Hz,1H),6.43(d,J=2.2Hz,1H),6.41(s,1H),2.42(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.01,159.79,155.60,155.19,152.73,149.51,146.56,144.56,144.03,141.78,139.96,137.65,135.12,130.53,130.21,128.20,128.20,126.39,125.99,125.22,123.38,120.51,112.50,94.79,87.62,25.14.
HR-ESI-MS Calcd.for C26H17N5O3F4[M+H]+:508.13819;found:508.13890.
Example 5
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 4-OCH3The compound is numbered as GMZC-Q-5.
The preparation method of the compound GMZC-Q-5 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (4-methoxyphenyl) -2-pyridinecarboxylic acid: the synthesis method is similar to step (5) of example 1, except that this step replaces 4-fluorophenylboronic acid of example 1 with an equimolar amount of 4-methoxyphenylboronic acid, and the remaining conditions are unchanged. Finally obtaining 0.403g of light yellow solid, namely the intermediate 6- (4-methoxyphenyl) -2-pyridinecarboxylic acid (b)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 86%.
1H NMR(400MHz,DMSO-d6)δ8.16(s,1H),8.14(s,1H),8.10(s,1H),8.03~7.97(m,1H),7.92(s,1H),7.06(s,1H),3.82(s,3H).
13C NMR(101MHz,DMSO-D6)δ166.79,165.31,161.04,156.28,148.57,141.24,138.93,130.72,128.84,124.85,123.05,114.68,55.79.
HR-ESI-MS Calcd.forC13H11NO3[M+H]+:230.08125;found:230.08134.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (4-methoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally obtaining 0.178g of white solid, namely the product 7- [ 2-fluoro-4- (6- (4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 58%.
1H NMR(400MHz,DMSO-d6)δ10.03(s,1H),8.30~8.24(m,1H),8.19~8.17(m,1H),8.17~8.15(m,1H),8.15(s,1H),8.14(d,J=1.0Hz,1H),8.14~8.08(m,1H),7.65~7.60(m,1H),7.58(t,J=5.3Hz,1H),7.45(dd,J=8.7,1.4Hz,1H),7.13~7.10(m,1H),7.09~7.08(m,1H),6.43(d,J=2.2Hz,1H),6.40(s,1H),3.83(s,3H),2.42(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.27,161.27,157.00,155.22,152.76,149.45,146.20,145.85,144.60,144.03,139.33,135.09,130.43,128.85,128.85,125.24,124.30,120.54,114.84,114.84,112.72,112.50.94.76,87.60,55.83,26.86.
HR-ESI-MS Calcd.forC26H20N5O3F[M+H]+470.16237; found 470.16216 EXAMPLE 6
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 4-OCF3The compound is numbered as GMZC-Q-8.
The preparation method of the compound GMZC-Q-8 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid: the synthesis was similar to step (5) of example 1, except that this step replaced 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 4-trifluoromethoxyphenylboronic acid, and the remaining conditions were unchanged. Finally obtaining 0.471g of light yellow solid, namely the intermediate 6- (4-trifluoromethoxyphenyl) -2-pyridine carboxylic acid (b)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 81%.
1H NMR(400MHz,DMSO-d6)δ8.33(s,1H),8.30(d,J=5.2Hz,1H),8.24(d,J=8.4Hz,1H),8.13~8.06(m,1H),8.03(s,1H),7.53(d,J=3.5Hz,1H),7.50(s,1H).
13C NMR(101MHz,DMSO-D6)δ166.59,155.10,149.82,148.87,139.36,137.50,136.69,129.47,129.47,124.11,121.88,121.76,119.33.
HR-ESI-MS Calcd.for C13H8NO3F3[M+H]+:284.05298;found:284.05258.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally obtaining 0.188g of white solid, namely the product 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 55%.
1H NMR(400MHz,DMSO-d6)δ9.99(s,1H),8.33(dd,J=7.8,1.2Hz,1H),8.30~8.27(m,1H),8.27~8.24(m,1H),8.22(dd,J=7.7,1.1Hz,1H),8.20~8.13(m,1H),8.10(d,J=2.2Hz,1H),7.58(dd,J=7.7,4.0Hz,1H),7.56~7.52(m,1H),7.52~7.49(m,1H),7.48(t,J=1.9Hz,1H),7.44~7.39(m,1H),6.38(dd,J=3.8,1.4Hz,1H),6.36(s,1H),2.37(s,3H).
13C NMR(101MHz,DMSO-d6)δ163.06,159.77,155.83,155.20,152.74,149.99,149.51,146.42,144.55,144.01,139.76,137.63,137.17,135.01,129.47,129.47,125.41,125.19,121.84,121.84,120.47,112.69,112.48,94.78,87.60,25.13.
HR-ESI-MS Calcd.for C26H17N5O3F4[M+H]+:524.13311;found:524.13372.
Example 7
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-formyl 4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 3-CHO and 4-OCH3The compound is numbered as GMZC-Q-9.
The preparation method of the compound GMZC-Q-9 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid: the synthesis method is similar to step (5) of example 1, except that this step replaces 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 3-formyl-4-methoxybenzeneboronic acid, and the rest of the conditions are unchanged. Finally, 0.449g of light yellow solid is obtained, namely the intermediate 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid (I)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 85%.
1H NMR(400MHz,)δ10.36(d,J=1.5Hz,1H),8.45(d,J=2.3Hz,1H),8.42(dd,J=8.7,2.5Hz,1H),8.14(dt,J=6.3,3.1Hz,1H),8.01~7.96(m,1H),7.94~7.91(m,1H),7.32(d,J=8.8Hz,1H),3.97~3.92(m,3H).
13C NMR(101MHz,)δ189.61,166.69,162.89,155.20,148.77,141.22,139.16,135.07,130.78,126.88,124.74,123.31,113.68,56.80.
HR-ESI-MS Calcd.for C14H11NO4[M+H]+:258.07516;found:258.07592.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally, 0.166g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 51%.
1H NMR(400MHz,DMSO-d6)δ10.39~10.39(m,1H),9.98(d,J=28.7Hz,1H),8.49(t,J=3.0Hz,1H),8.45(dd,J=8.8,2.5Hz,1H),8.32(dt,J=4.2,2.1Hz,1H),8.20~8.16(m,1H),8.15(dd,J=7.3,3.0Hz,1H),8.11(t,J=1.5Hz,1H),7.60~7.56(m,1H),7.55(dd,J=6.5,3.7Hz,1H),7.44~7.40(m,1H),7.40~7.36(m,1H),6.39~6.38(m,1H),6.37(d,J=3.4Hz,1H),3.97(d,J=2.9Hz,3H),2.38(s,3H).
13C NMR(101MHz,DMSO-D6)δ189.59,172.54,170.86,163.15,163.11,155.93,155.20,152.75,149.34,146.30,144.67,144.07,139.66,135.07,130.47,126.84,125.26,124.91,124.83,120.59,113.91,112.79,100.00,94.71,87.64,56.87,31.66.
HR-ESI-MS-ESI Calcd.for C27H20N5 O4F[M+H]+:498.15629;found:498.15658.
Example 8
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 3-OCH3And 4-OCH3The compound is numbered as GMZC-Q-12.
The preparation method of the compound GMZC-Q-12 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid: the synthesis was similar to step (5) of example 1, except that this step replaced 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 3, 4-dimethoxyphenylboronic acid, and the rest of the conditions were unchanged. Finally, 0.449g of light yellow solid is obtained, namely the intermediate 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid (I)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 85%.
1H NMR(400MHz,DMSO-d6)δ8.12(s,1H),8.02(s,1H),7.99~7.93(m,1H),7.84(s,1H),7.70(s,1H),7.04(s,1H),3.83(s,3H),3.78(s,3H).
13C NMR(101MHz,DMSO-D6)δ166.75,165.31,156.38,150.76,149.48,148.49,141.23,138.87,132.08,124.84,120.29,112.21,56.18,56.08.
HR-ESI-MS Calcd.for C14H13NO4[M+H]+:260.09181;found:260.09174.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that in this step 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 is replaced by an equimolar amount of 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally, 0.163g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 50%.
1H NMR(400MHz,DMSO-d6)δ10.03(s,1H),8.37~8.29(m,1H),8.19~8.16(m,1H),8.15(d,J=1.4Hz,1H),8.15~8.10(m,1H),7.82~7.78(m,1H),7.78(d,J=1.4Hz,1H),7.61(d,J=8.7Hz,1H),7.60~7.57(m,1H),7.45(dd,J=8.7,1.4Hz,1H),7.15~7.08(m,1H),6.43(d,J=2.2Hz,1H),6.40(s,1H),3.87(d,J=4.0Hz,3H),3.84(s,3H),2.42(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.24,159.79,157.08,155.22,152.76,151.01,149.55,147.63,146.14,144.61,144.04,139.28,137.54,135.25,130.61,125.25,124.60,124.37,120.39,112.38,110.70,100.00,94.78,87.59,56.15,56.13,31.67.
HR-MS-ESI Calcd.for C27H22N5O4F[M+H]+:500.17294;found:500.17233.
Example 9
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 3-OCH3And 5-OCH3The compound is numbered as GMZC-Q-13.
The preparation method of the compound GMZC-Q-13 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid: the synthesis was similar to step (5) of example 1, except that this step replaced 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 3, 5-dimethoxyphenylboronic acid, and the rest of the conditions were unchanged. Finally obtaining 0.429g of light yellow solid, namely the intermediate 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid (II)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 81%.
1H NMR(400MHz,)δ8.20(dd,J=7.7,1.2Hz,1H),8.08~8.02(m,1H),8.00(dd,J=7.6,1.2Hz,1H),7.33(s,1H),7.33(s,1H),6.61(t,J=2.3Hz,1H),3.83(s,6H).
13C NMR(101MHz,)δ166.68,165.32,161.39,156.17,148.59,141.23,140.37,139.06,132.09,124.28,105.52,101.87,55.90,55.90.
HR-ESI-MS Calcd.for C14H13NO4[M+H]+:260.09181;found:260.09177.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that in this step 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 is replaced by an equimolar amount of 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally, 0.170g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 52%.
1H NMR(400MHz,DMSO-d6)δ10.04(s,1H),8.36(dd,J=7.9,1.1Hz,1H),8.24(dd,J=7.7,1.0Hz,1H),8.17(dd,J=9.3,5.8Hz,1H),8.15(d,J=2.2Hz,1H),7.65~7.61(m,1H),7.59(dd,J=8.6,4.0Hz,1H),7.45(dd,J=8.8,1.4Hz,1H),7.37~7.35(m,1H),7.35(s,1H),6.66(t,J=2.3Hz,1H),6.42(d,J=2.2Hz,1H),6.40(s,1H),3.84(s,6H),2.41(s,3H).
13C NMR(101MHz,DMSO-D6)δ175.03,163.13,161.50,161.50,159.79,156.81,155.20,152.74,149.50,147.62,146.20,144.59,144.03,140.04,139.51,132.06,129.33,125.21,120.57,112.75,105.58,101.98,94.78,87.58,55.93,55.93,31.66.
HR-ESI-MS Calcd.for C27H22N5O4F[M+H]+:500.17294;found:500.17260.
Example 10
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is H, R3Is 3-OCH3The compound is numbered as GMZC-Q-19.
The preparation method of the compound GMZC-Q-19 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6- (3-methoxyphenyl) -2-pyridinecarboxylic acid: the synthesis method is similar to step (5) of example 1, except that this step replaces 4-fluorophenylboronic acid of example 1 with an equimolar amount of 3-methoxyphenylboronic acid, and the remaining conditions are unchanged. Finally obtaining 0.384g of light yellow solid, namely the intermediate 6- (3-methoxyphenyl) -2-pyridinecarboxylic acid (b)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 82%.
1H NMR(400MHz,)δ8.20(td,J=7.5,1.2Hz,1H),8.08~8.02(m,1H),8.00(dd,J=7.6,1.2Hz,1H),7.74(d,J=1.8Hz,1H),7.73(dd,J=3.2,1.3Hz,1H),7.46~7.38(m,1H),7.04(ddd,J=8.2,2.5,0.8Hz,1H),3.84(s,3H).
13C NMR(101MHz,)δ166.70,160.23,156.25,148.71,139.73,139.05,130.40,124.07,123.86,119.71,115.59,112.80,55.71.
HR-ESI-MS Calcd.for C13H11NO3[M+H]+:230.08125;found:230.08136.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3-methoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions are unchanged. Finally obtaining 0.166g of white solid, namely the product 7- [ 2-fluoro-4- (6- (3-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 56%.
1H NMR(400MHz,DMSO-d6)δ10.03(s,1H),8.36(dd,J=7.9,1.1Hz,1H),8.24(dd,J=7.7,1.1Hz,1H),8.21~8.16(m,1H),8.15(d,J=2.2Hz,1H),7.77(ddd,J=7.8,1.6,0.9Hz,1H),7.74(dd,J=2.4,1.6Hz,1H),7.65~7.60(m,1H),7.60~7.57(m,1H),7.47(dd,J=6.4,4.6Hz,1H),7.45(ddd,J=3.5,3.0,1.0Hz,1H),7.09(ddd,J=8.3,2.6,0.9Hz,1H),6.45~6.42(m,1H),6.41(s,1H),3.86(d,J=1.9Hz,3H),2.42(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.16,160.33,159.80,156.97,155.21,152.75,149.51,146.29,144.59,144.04,139.56,139.45,137.58,137.48,135.08,130.63,125.22,120.57,119.75,115.80,112.93,112.75,94.78,87.60,55.78,25.14.
HR-ESI-MS Calcd.for C26H20N5O3F[M+H]+:470.16237;found:470.16229.
Example 11
The pyridine amide compound is 7- [ 2-fluoro-4- (6 '-methoxy- [2,3' -bipyridine)]-6-carboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines, of the general structural formula (II), R1Is CH3,R2Is H, R3Is 6-OCH3The compound is numbered as GMZC-Q-21.
The preparation method of the compound GMZC-Q-21 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6 '-methoxy- [2,3' -bipyridine]-6-carboxylic acid: the synthesis is similar to step (5) of example 1, except that this step is carried out using an equimolar amount of 2-methoxy-5-pyridineboronic acid instead of4-Fluorophenylboronic acid from example 1, with the remaining conditions unchanged. Finally obtaining 0.386g of light yellow solid, namely the intermediate 6 '-methoxy- [2,3' -bipyridine]6-carboxylic acid(s) (iii)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 82%.
1H NMR(400MHz,DMSO-d6)δ8.92(dd,J=2.5,0.7Hz,1H),8.45(ddd,J=7.3,2.8,1.3Hz,1H),8.15(dd,J=7.9,1.1Hz,1H),8.04~7.98(m,1H),7.97~7.87(m,1H),6.95~6.87(m,1H),3.88(d,J=1.9Hz,3H).
13C NMR(101MHz,DMSO-D6)δ166.57,164.85,154.38,148.71,146.40,139.17,138.19,127.74,123.51,123.38,111.10,53.99.
HR-ESI-MS Calcd.for C12H10N2O3[M+H]+:231.07650;found:231.07643.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6 '-methoxy- [2,3' -bipyridine)]-6-carboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (6) of example 1, except that this step uses an equimolar amount of 6 '-methoxy- [2,3' -bipyridine]-6-Carboxylic acid instead of 6- (4-fluorophenyl) -2-pyridinecarboxylic acid from example 1, the other conditions remaining unchanged. Finally, 0.175g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6 '-methoxy- [2,3' -bipyridine)]-6-carboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 56%.1H NMR(400MHz,DMSO-d6)δ10.01(s,1H),9.00~8.89(m,1H),8.45(dd,J=8.7,2.6Hz,1H),8.32(dd,J=7.5,1.4Hz,1H),8.18(dd,J=7.7,1.3Hz,1H),8.14(dd,J=9.3,5.8Hz,1H),8.11(d,J=2.2Hz,1H),7.57(t,J=5.3Hz,1H),7.54(dd,J=10.1,3.1Hz,1H),7.41(dd,J=8.6,1.5Hz,1H),6.96(dd,J=8.7,0.6Hz,1H),6.39(d,J=2.2Hz,1H),6.37(s,1H),3.89(d,J=8.4Hz,3H),2.38(s,3H).
13C NMR(101MHz,DMSO-D6)δ182.93,169.07,165.03,163.09,159.78,156.69,155.13,152.73,146.45,146.37,144.59,144.05,139.62,138.13,129.72,127.54,125.24,124.94,124.68,120.53,111.34,100.00,87.60,54.07,30.34.
HR-ESI-MS Calcd.for C25H19N6O3F[M+H]+:471.15762;foun d:471.15760.
Example 12
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is CH3,R3Is 3-CHO and 4-OCH3The compound is numbered as GMZC-Q-22.
The preparation method of the compound GMZC-Q-22 comprises the following steps:
(1) synthesis of intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (1) of example 1, except that this step replaces the ethyl acetoacetate of example 1 with an equimolar amount of ethyl 2-methylacetoacetate, and the remaining conditions are unchanged. Finally, 5.901g of white solid is obtained, namely the intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1, 5-a)]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 57%.
1H NMR(400MHz,DMSO-d6)δ12.10(s,1H),7.81~7.77(m,1H),6.02(dd,J=2.5,1.4Hz,1H),2.29~2.21(m,3H),1.94(t,J=2.3Hz,3H).
13C NMR(101MHz,DMSO-d6)δ157.58,146.37,143.10,141.28,100.91,87.74,17.92,10.82.
HR-ESI-MS Calcd.for C8H9N3O[M+H]+:164.08159;found:164.08184.
(2) Synthesis of intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (2) of example 1, except that this step uses an equimolar amount of 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ]]Pyrimidine substituted 5-methyl-7-hydroxy-pyrazolo [1,5-a ] of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 1.501g of yellow liquid is obtained, namely the intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1, 5-a)]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 50%.
1H NMR(400MHz,CDCl3)δ8.06(t,J=2.0Hz,1H),6.59(dd,J=3.3,1.5Hz,1H),2.57(d,J=2.5Hz,3H),2.39(d,J=2.6Hz,3H).
13C NMR(101MHz,CDCl3)δ158.78,147.74,144.41,115.50,97.10,24.22,14.81.
HR-ESI-MS Calcd.for C8H8N3Cl[M+H]+:182.04795;found:182.04771.
(3) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (3) of example 1, except that this step uses an equimolar amount of 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ]]Pyrimidine substitution of 5-methyl-7-chloro-pyrazolo [1,5-a ] of example 1]Pyrimidine, the rest conditions were unchanged. Finally obtaining 0.903g of yellow-green solid, namely the intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 50%.
1H NMR(400MHz,CDCl3)δ8.12(dt,J=8.5,4.3Hz,1H),7.96(ddd,J=9.1,2.6,1.6Hz,1H),7.93(d,J=2.3Hz,1H),6.79(dd,J=9.0,7.8Hz,1H),6.61(d,J=2.3Hz,1H),2.66(s,3H),2.32(d,J=2.7Hz,3H).
13C NMR(101MHz,CDCl3)δ161.21,152.46,149.93,148.86,148.08,144.84,120.58,116.99,113.80,113.58,106.79,96.64,23.80,11.02.
HR-ESI-MS Calcd.for C14H11N4O3F[M+H]+:303.08979;found:303.08970.
(4) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (4) of example 1, except that this step is carried out using an equimolar amount of 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.650g of white solid is obtained, namely the intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo[1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 72%.
1H NMR(400MHz,DMSO-d6)δ9.64(s,1H),9.04(s,1H),8.02(dd,J=3.9,1.6Hz,1H),6.89(dd,J=8.5,1.5Hz,1H),6.88~6.85(m,1H),6.67(ddd,J=7.1,4.4,2.7Hz,1H),6.40(d,J=2.3Hz,1H),2.43(s,3H),1.81(s,3H).
13C NMR(101MHz,DMSO-d6)δ160.46,152.32,149.93,147.71,143.07,141.86,141.28,132.74,117.96,110.38,100.29,94.64,24.21,14.57.
HR-ESI-MS Calcd.for C14H 13N4OF[M+H]+:273.11462;found:273.11463.
(5) Synthesis of intermediate 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid: the synthesis method was the same as in step (5) of example 7.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid, and 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] with an equimolar amount of 5, 6-dimethyl]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally obtaining 0.167g of white solid, namely the product 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 48%.
1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),9.48(d,J=14.8Hz,1H),8.49(s,1H),8.48~8.43(m,1H),8.32(dd,J=7.5,1.4Hz,1H),8.29~8.16(m,1H),8.14(dd,J=6.3,3.6Hz,1H),8.08(dd,J=28.8,5.0Hz,1H),7.40(s,1H),7.37(dd,J=10.3,7.3Hz,1H),6.95(dd,J=12.3,2.5Hz,1H),6.83(dd,J=27.0,8.3Hz,1H),6.47(d,J=2.2Hz,1H),4.12~3.92(m,3H),2.76~2.49(m,3H),2.13~1.95(m,3H).
13C NMR(101MHz,DMSO-D6)δ189.58,163.32,163.07,160.69,155.85,147.87,146.42,143.29,141.16,140.42,139.62,137.34,136.21,135.35,135.08,130.46,126.81,124.76,124.55,117.26,115.17,113.89,104.59,100.00,95.22,56.85,24.23,14.70.
HR-ESI-MS Calcd.for C28H22N5O4F[M+H]+:512.17294;found:512.17285.
Example 13
The pyridine amide compound is 7- [ 2-fluoro-4- (6 '-fluoro- [2,3' -bipyridine)]-6-carboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidines, of the general structural formula (II), R1Is CH3,R2Is H, R3Is 6-F, and the compound number is GMZC-Q-23.
The preparation method of the compound GMZC-Q-23 comprises the following steps:
(1) synthesis of intermediate 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 1.
(2) Synthesis of intermediate 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 1.
(3) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 1.
(4) Synthesis of intermediate 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 1.
(5) Synthesis of intermediate 6 '-fluoro- [2,3' -bipyridine]-6-carboxylic acid: the synthesis method is similar to step (5) of example 1, except that this step replaces 4-fluorobenzeneboronic acid of example 1 with an equimolar amount of 2-fluoro-5-pyridineboronic acid, and the rest of the conditions are unchanged. Finally, light yellow solid 0.345g is obtained, namely the intermediate 6 '-fluoro- [2,3' -bipyridine]6-carboxylic acid(s) (iii)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 77%.
1H NMR(400MHz,DMSO-d6)δ9.02(s,1H),8.75(s,1H),8.27(d,J=8.2Hz,1H),8.10(d,J=9.0Hz,1H),8.04(d,J=7.4Hz,1H),7.58(dd,J=20.1,9.6Hz,1H),7.34(d,J=8.7Hz,1H);
13C NMR(101MHz,DMSO-d6)δ166.41,162.97,153.20,148.88,146.85,141.20,139.48,133.72,129.33,124.33,110.42;
HR-MS-ESI Calcd.for C11H7N2O2F[M+H]+:219.05651;found:219.05634。
(6) Synthesis of the product 7- [ 2-fluoro-4- (6 '-fluoro- [2,3' -bipyridine)]-6-carboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (6) of example 1, except that this step uses an equimolar amount of 6 '-fluoro- [2,3' -bipyridine]-6-Carboxylic acid instead of 6- (4-fluorophenyl) -2-pyridinecarboxylic acid from example 1, the other conditions remaining unchanged. Finally, 0.146g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6 '-fluoro- [2,3' -bipyridine)]-6-carboxamido) phenoxy]-5-methylpyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 48%.
1H NMR(400MHz,DMSO-d6)δ10.02(s,1H),9.00(d,J=2.6Hz,1H),8.70(tt,J=12.8,3.7Hz,1H),8.41(dd,J=7.7,1.2Hz,1H),8.30~8.24(m,1H),8.21(dd,J=9.6,5.9Hz,1H),8.11(d,J=2.2Hz,1H),7.61~7.56(m,1H),7.56~7.52(m,1H),7.45~7.38(m,1H),7.38~7.33(m,1H),6.39(t,J=2.8Hz,1H),6.37(s,1H),2.38(s,3H);
13C NMR(101MHz,DMSO-d6)δ175.03,165.47,163.10,162.94,155.17,153.99,152.71,147.03,146.52,144.59,144.06,141.24,139.96,134.97,132.37,125.73,125.20,120.56,112.72,110.30,100.00,94.76,87.62,22.63;
HR-MS-ESI Calcd.for C24H16N6O2F2[M+H]+:459.137 64;found:459.13768。
Example 14
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine formamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is CH3,R3Is 6-OCF3The compound is numbered as GMZC-Q-24.
The preparation method of the compound GMZC-Q-24 comprises the following steps:
(1) synthesis of intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 12.
(2) Synthesis of intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 12.
(3) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 12.
(4) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 12.
(5) Synthesis of intermediate 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 6.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid, and 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] with an equimolar amount of 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ]]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.153g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 43%.
1H NMR(400MHz,DMSO-d6)δ9.47(s,1H),8.34~8.31(m,1H),8.27(d,J=2.0Hz,1H),8.26(d,J=2.1Hz,1H),8.22~8.18(m,1H),8.15(t,J=7.6Hz,1H),8.03(d,J=2.2Hz,1H),7.53~7.50(m,1H),7.50~7.47(m,1H),7.35(t,J=8.8Hz,1H),6.94(dd,J=12.2,2.5Hz,1H),6.81~6.73(m,1H),6.46(d,J=2.3Hz,1H),2.64(s,3H),1.95(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.25,160.66,155.76,155.18,152.74,149.97,147.90,146.56,143.28,141.08,140.44,137.19,132.16,129.47,129.47,125.33,124.53,121.86,121.86,119.32,115.18,107.17,104.59,95.22,38.74,24.20,14.66.
HR-ESI-MS Calcd.for C27H19N5 O3F4[M+H]+:538.14972;found:538.14935.
Example 15
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is CH3,R3Is 3-OCH3And 5-OCH3The compound is numbered as GMZC-Q-25.
The preparation method of the compound GMZC-Q-25 comprises the following steps:
(1) synthesis of intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 12.
(2) Synthesis of intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 12.
(3) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 12.
(4) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 12.
(5) Synthesis of intermediate 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 9.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid, and an equimolar amount of 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] is used]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, a white solid 0.1 was obtained97g is the product 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 58%.
1H NMR(400MHz,DMSO-d6)δ9.47(s,1H),8.32(dd,J=7.8,0.8Hz,1H),8.19(d,J=6.7Hz,1H),8.13(t,J=7.7Hz,1H),8.04(d,J=2.3Hz,1H),7.42~7.33(m,1H),7.31(s,1H),7.30(s,1H),6.95(dd,J=12.2,2.5Hz,1H),6.79(dd,J=8.7,1.9Hz,1H),6.63(t,J=2.2Hz,1H),6.48(d,J=2.2Hz,1H),3.82(d,J=4.9Hz,3H),3.80(s,3H),2.49(s,3H),1.97(d,J=6.0Hz,3H).
13C NMR(101MHz,DMSO-D6)δ163.30,161.48,161.48,160.68,156.78,155.19,152.74,147.89,146.34,143.30,141.16,140.45,140.07,139.48,132.19,125.28,124.56,115.14,107.14,105.56,105.56,104.64,101.96,95.22,55.93,55.93,24.23,14.67.
HR-ESI-MS Calcd.for C28H24N5O4F[M+H]+:514.18859;found:514.18872.
Example 16
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine carboxamide) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is CH3,R3Is 4-F, and the compound number is GMZC-Q-26.
The preparation method of the compound GMZC-Q-26 comprises the following steps:
(1) synthesis of intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 12.
(2) Synthesis of intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 12.
(3) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 12.
(4) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 12.
(5) Synthesis of intermediate 6- (4-fluorophenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 1.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis procedure is similar to step (6) of example 1, except that this step is carried out using an equimolar amount of 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1, 5-a)]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.187g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine carboxamide) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 61%.
1H NMR(400MHz,DMSO-d6)δ9.49(s,1H),8.33(dd,J=7.3,1.6Hz,1H),8.28~8.24(m,1H),8.23(d,J=5.5Hz,1H),8.19(t,J=3.9Hz,1H),8.15(d,J=7.7Hz,1H),8.05(t,J=5.2Hz,1H),7.42~7.38(m,1H),7.37(s,1H),7.35(d,J=2.1Hz,1H),6.97(dd,J=12.2,2.4Hz,1H),6.81(dd,J=8.7,2.1Hz,1H),6.50(d,J=2.2Hz,1H),2.50(s,3H),1.98(d,J=5.8Hz,3H).
13C NMR(101MHz,DMSO-D6)δ165.03,163.32,162.57,160.69,156.12,155.18,147.90,146.46,143.30,141.17,140.45,139.65,134.50,132.29,129.65,124.94,124.94,124.55,116.50,116.29,115.15,107.15,104.63,95.23,24.24,14.68.
HR-ESI-MSCalcd.for C26H19N5O2F2[M+H]+:472.15704;found:472.15780.
Example 17
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is CH3,R3Is 3-F and 4-OCH3The compound is numbered as GMZC-Q-27.
The preparation method of the compound GMZC-Q-27 comprises the following steps:
(1) synthesis of intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 12.
(2) Synthesis of intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 12.
(3) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 12.
(4) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 12.
(5) Synthesis of intermediate 6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 2.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis procedure is similar to step (6) of example 2, except that this step uses an equimolar amount of 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 2]Pyrimidine, the rest conditions were unchanged. Finally obtaining 0.203g of white solid, namely the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 62%.
1H NMR(400MHz,DMSO-d6)δ9.49(s,1H),8.30(dd,J=7.2,1.7Hz,1H),8.15(dd,J=7.3,1.4Hz,1H),8.11(d,J=7.5Hz,1H),8.05(d,J=2.3Hz,1H),8.03(dd,J=5.6,2.6Hz,1H),8.00(dd,J=5.7,2.6Hz,1H),7.37(t,J=8.8Hz,1H),7.31(dd,J=12.2,5.7Hz,1H),6.96(dd,J=12.2,2.5Hz,1H),6.83~6.77(m,1H),6.49(d,J=2.3Hz,1H),3.89(d,J=6.3Hz,3H),2.49(s,3H),1.97(d,J=5.5Hz,3H).
13C NMR(101MHz,DMSO-D6)δ163.31,160.68,155.69,155.19,153.46,152.74,151.04,149.04,147.89,146.36,143.30,141.16,140.45,139.52,132.18,130.96,124.55,123.93,115.16,114.68,114.49,107.38,104.62,95.23,56.67,24.23,14.68.
HR-ESI-MS Calcd.for C27H21N5 O3F2[M+H]+:502.16860;found:502.16856.
Example 18
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is CH3,R3Is 3-OCH3And 4-OCH3The compound is numbered as GMZC-Q-28.
The preparation method of the compound GMZC-Q-28 comprises the following steps:
(1) synthesis of intermediate 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 12.
(2) Synthesis of intermediate 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 12.
(3) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 12.
(4) Synthesis of intermediate 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 12.
(5) Synthesis of intermediate 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 8.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine: similar to step (6) of example 8, except that this step was performed with an equimolar amount of 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 8]Pyrimidine, the rest conditions were unchanged. Obtaining 0.165g of white solid, namely the product 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5, 6-dimethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 49%.
1H NMR(400MHz,DMSO-d6)δ9.48(s,1H),8.29(dd,J=7.3,1.7Hz,1H),8.14~8.07(m,2H),8.05(d,J=2.2Hz,1H),7.77(dd,J=8.3,2.0Hz,1H),7.75(d,J=1.9Hz,1H),7.38(t,J=8.8Hz,1H),7.09(t,J=6.0Hz,1H),6.96(dd,J=12.2,2.5Hz,1H),6.80(dd,J=8.7,1.9Hz,1H),6.49(d,J=2.2Hz,1H),3.85(s,3H),3.82(s,3H),2.50(s,3H),1.99(s,3H).
13C NMR(101MHz,DMSO-D6)δ163.41,160.67,157.03,155.21,152.76,150.97,149.53,147.90,146.29,143.30,141.14,140.46,139.23,132.37,130.63,124.56,124.26,120.38,115.15,112.36,110.68,107.15,104.64,95.23,56.15,56.11,24.22,14.66.
HR-ESI-MS Calcd.for C28H24N5O4F[M+H]+:514.18859;found:514.18871.
Example 19
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine formamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is C2H5,R3Is 4-OCF3The compound is numbered as GMZC-Q-29.
The preparation method of the compound GMZC-Q-29 comprises the following steps:
(1) synthesis of intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (1) of example 1, except that this step replaces the ethyl acetoacetate of example 1 with an equimolar amount of ethyl 2-ethylacetoacetate, and the remaining conditions are unchanged. Finally, 5.012g of white solid is obtained, namely the intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 49%.
1H NMR(400MHz,DMSO-d6)δ12.03(s,1H),7.76~7.74(m,1H),6.05~5.82(m,1H),2.40(q,J=7.4Hz,2H),2.27(s,3H),0.97(t,J=7.4Hz,3H).
13C NMR(101MHz,DMSO-D6)δ157.17,146.07,143.13,141.32,107.33,87.80,18.65,17.22,14.09.
HR-ESI-MS Calcd.for C9H11N3O[M+H]+:178.09757;found:178.09752.
(2) Synthesis of intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (2) of example 1, except that this step uses an equimolar amount of 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ]]Pyrimidine substituted 5-methyl-7-hydroxy-pyrazolo [1,5-a ] of example 1]Pyrimidine, the rest conditions were unchanged. Finally obtaining 1.902g of light yellow liquid, namely the intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 57%.
1H NMR(400MHz,CDCl3)δ8.06(t,J=3.4Hz,1H),6.58(d,J=2.3Hz,1H),2.85~2.77(m,2H),2.60(s,3H),1.22~1.16(m,3H).
13C NMR(101MHz,CDCl3)δ158.33,147.77,144.58,136.51,121.11,97.08,23.45,22.39,13.09.
HR-ESI-MS Calcd.for C9H10N3Cl[M+H]+:196.06337;found:196.06373.
(3) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine: the synthesis is similar to step (3) of example 1, except that this step uses an equimolar amount of 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ]]Pyrimidine substitution of 5-methyl-7-chloro-pyrazolo [1,5-a ] of example 1]Pyrimidine, the rest conditions were unchanged. Finally obtaining 1.209g of yellow-green solid, namely the intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 54%.
1H NMR(400MHz,CDCl3)δ8.13(dt,J=13.0,4.1Hz,1H),8.02~7.93(m,1H),7.93(d,J=2.3Hz,1H),6.84~6.71(m,1H),6.60(d,J=2.3Hz,1H),2.78(q,J=7.5Hz,2H),2.70(s,3H),1.48~1.31(m,3H).
13C NMR(101MHz,CDCl3)δ160.73,152.41,149.88,148.85,146.49,144.98,143.81,120.57,116.98,113.55,112.74,96.55,23.14,19.00,14.12.
HR-ESI-MS Calcd.for C15H13N4O3F[M+H]+:317.10425;found:317.10441.
(4) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a]Pyrimidine: the synthesis procedure is similar to step (4) of example 1, except that this step is carried out using an equimolar amount of 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.650g of white solid is obtained, namely the intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 72%.
1H NMR(400MHz,DMSO-d6)δ9.63(s,1H),8.77(s,1H),8.04~7.84(m,1H),6.84(dd,J=5.1,2.5Hz,1H),6.82(dd,J=7.4,2.1Hz,1H),6.66~6.60(m,1H),6.37~6.32(m,1H),2.45(s,3H),2.43~2.35(m,2H),0.85(t,J=7.4Hz,3H).
13C NMR(101MHz,DMSO-D6)δ159.55,152.22,149.82,147.75,143.21,142.10,132.79,119.12,117.92,111.46,107.29,94.54,23.75,19.68,13.94.
HR-ESI-MS Calcd.for C13H11N4OF[M+H]+:287.13054;found:287.13004.
(5) Synthesis of intermediate 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid: the synthesis method was the same as in step (5) of example 6.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid, and an equimolar amount of 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] is used]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, a white solid of 0.21 is obtained0g is the product 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine formamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 58%.
1H NMR(400MHz,DMSO-d6)δ9.23(s,1H),8.33(dd,J=7.3,1.7Hz,1H),8.28~8.25(m,1H),8.23(dd,J=5.2,3.0Hz,1H),8.20(dd,J=7.7,1.6Hz,1H),8.19~8.13(m,1H),8.05~8.02(m,1H),7.42~7.38(m,1H),7.38~7.35(m,1H),7.33(t,J=8.8Hz,1H),6.80(dd,J=12.2,2.6Hz,1H),6.69~6.63(m,1H),6.50(d,J=2.3Hz,1H),2.66(dddd,J=16.0,12.6,4.3,2.8Hz,2H),2.58(s,3H),1.05(t,J=7.4Hz,3H).
13C NMR(101MHz,DMSO-D6)δ165.02,163.34,162.56,159.62,156.11,155.05,152.61,148.04,146.46,143.57,141.94,140.30,139.66,134.52,131.91,129.74,124.95,124.37,116.51,116.29,113.07,106.92,100.00,95.21,38.76,23.69,20.24,14.24.
HR-ESI-MS Calcd.forC28H21N5O3F4[M+H]+:552.50361;found:552.50301.
Example 20
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is C2H5,R3Is 3-OCH3And 5-OCH3The compound is numbered as GMZC-Q-30.
The preparation method of the compound GMZC-Q-30 comprises the following steps:
(1) synthesis of intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 19.
(2) Synthesis of intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 19.
(3) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 19.
(4) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 19.
(5) Synthesis of intermediate 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 9.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid, and 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] with an equimolar amount of 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ]]Pyrimidine substituted for 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.227g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 66%.
1H NMR(400MHz,CDCl3)δ8.24~8.17(m,1H),7.99~7.96(m,1H),7.95(t,J=2.0Hz,1H),7.94(d,J=2.3Hz,1H),7.70(s,1H),7.35~7.31(m,1H),7.31~7.26(m,1H),7.24~7.23(m,1H),6.97(dd,J=10.7,2.4Hz,1H),6.94(dd,J=6.0,3.4Hz,1H),6.55(t,J=2.3Hz,1H),6.51(d,J=2.3Hz,1H),3.87(s,6H),2.61(s,3H),2.50(q,J=7.4Hz,2H),1.03~0.95(m,3H).
13CNMR(101MHz,CDCl3)δ163.09,161.34,160.44,157.88,155.54,153.04,147.29,146.58,143.28,140.93,140.38,138.95,138.01,135.40,124.63,124.38,123.57,119.10,117.87,110.76,107.96,105.53,101.76,95.69,55.63,55.63,23.62,20.33,13.28.
HR-ESI-MS Calcd.for C29H26N5O4F[M+H]+:528.20424;found:528.20403.
Example 21
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine carboxamide) phenoxy]-5-A6-ethylpyrazolo [1,5-a ] yl]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is C2H5,R3Is 4-F, and the compound number is GMZC-Q-31.
The preparation method of the compound GMZC-Q-31 comprises the following steps:
(1) synthesis of intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 19.
(2) Synthesis of intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 19.
(3) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 19.
(4) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 19.
(5) Synthesis of intermediate 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 9.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid, and an equimolar amount of 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ]]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.202g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine carboxamide) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 63%.
1H NMR(400MHz,DMSO-d6)δ9.18(s,1H),8.29(dd,J=7.3,1.7Hz,1H),8.22(dd,J=5.4,3.2Hz,1H),8.19(dd,J=5.2,3.0Hz,1H),8.15(dd,J=5.0,3.3Hz,1H),8.15~8.10(m,1H),8.01~7.97(m,1H),7.40~7.34(m,1H),7.34~7.31(m,1H),7.29(t,J=8.8Hz,1H),6.76(dd,J=12.2,2.6Hz,1H),6.65~6.60(m,1H),6.48~6.45(m,1H),2.64~2.58(m,2H),2.54(s,3H),1.01(t,J=7.4Hz,3H).
13C NMR(101MHz,DMSO-D6)δ165.03,163.34,162.57,159.62,156.12,155.06,152.61,148.05,146.47,143.57,141.85,140.30,139.65,134.50,132.05,129.65,124.93,124.39,116.50,116.28,114.71,113.07,106.70,95.21,23.69,20.24,14.24.
HR-ESI-MS Calcd.for C27H21N5O2F2[M+H]+:486.17369;found:486.17359.
Example 22
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is C2H5,R3Is 3-F and 4-OCH3The compound is numbered as GMZC-Q-32.
The preparation method of the compound GMZC-Q-32 comprises the following steps:
(1) synthesis of intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 19.
(2) Synthesis of intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 19.
(3) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 19.
(4) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 19.
(5) Synthesis of intermediate 6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 2.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step is carried out by substituting an equimolar amount of 6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxylic acidExample 1 6- (4-fluorophenyl) -2-pyridinecarboxylic acid, and 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] in equimolar amounts]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.223g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 66%.1H NMR(400MHz,DMSO-d6)δ9.18(s,1H),8.28(dd,J=7.0,2.1Hz,1H),8.12(dd,J=7.0,1.4Hz,1H),8.11~8.07(m,1H),8.03~8.00(m,1H),7.99(t,J=1.8Hz,1H),7.98(d,J=2.9Hz,1H),7.30(d,J=8.4Hz,1H),7.29~7.26(m,1H),6.76(dd,J=12.2,2.6Hz,1H),6.63(ddd,J=8.8,3.4,2.1Hz,1H),6.46(d,J=2.3Hz,1H),3.87(d,J=5.9Hz,3H),2.67~2.57(m,2H),2.53(d,J=6.5Hz,3H),1.06~0.98(m,3H).
13C NMR(101MHz,DMSO-D6)δ178.90,170.61,163.33,159.61,158.48,152.62,151.03,149.15,148.05,148.01,146.38,143.57,141.85,140.30,139.54,132.06,130.90,124.71,124.40,114.74,114.48,113.07,100.00,95.21,56.67,23.70,20.24,14.24.
HR-ESI-MS Calcd.for C28H23N5O3F2[M+H]+:516.18325;found:516.18394.
Example 23
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridine formamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is C2H5,R3Is 3-CHO and 4-OCH3The compound is numbered as GMZC-Q-33.
The preparation method of the compound GMZC-Q-33 comprises the following steps:
(1) synthesis of intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 19.
(2) Synthesis of intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 19.
(3) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 19.
(4) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 19.
(5) Synthesis of intermediate 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 7.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid, and 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] with an equimolar amount of 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ]]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally obtaining 0.197g of white solid, namely the product 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridine carboxamide) phenoxyl]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 57%.
1H NMR(400MHz,DMSO-d6)δ10.38(d,J=0.7Hz,1H),9.18(s,1H),8.47(d,J=2.3Hz,1H),8.45(dd,J=8.7,2.5Hz,1H),8.31(dt,J=10.5,5.2Hz,1H),8.15(dd,J=7.7,1.6Hz,1H),8.14~8.09(m,1H),7.99(d,J=2.3Hz,1H),7.38(d,J=8.8Hz,1H),7.34~7.25(m,1H),6.77(dd,J=12.2,2.6Hz,1H),6.65~6.60(m,1H),6.46(d,J=2.3Hz,1H),3.97(s,3H),2.67~2.57(m,2H),2.54(s,3H),1.02(t,J=7.4Hz,4H).
13C NMR(101MHz,DMSO-D6)δ189.60,178.03,163.34,163.09,159.61,155.88,152.62,148.05,146.47,143.57,141.86,140.30,139.64,135.09,132.05,131.92,130.50,126.85,124.80,124.58,114.75,113.92,113.07,95.21,91.52,56.88,23.70,20.24,14.25.
HR-ESI-MSCalcd.forC29H24N5O4F[M+H]+:526.18859;found:526.18889
Example 24
The pyridine amide compound is 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidines of the general structural formula (I), R1Is CH3,R2Is C2H5,R3Is 3-OCH3And 4-OCH3The compound is numbered as GMZC-Q-34.
The preparation method of the compound GMZC-Q-34 comprises the following steps:
(1) synthesis of intermediate 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (1) of example 19.
(2) Synthesis of intermediate 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 19.
(3) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 19.
(4) Synthesis of intermediate 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 19.
(5) Synthesis of intermediate 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 8.
(6) Synthesis of the product 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine: the synthesis method is similar to step (6) of example 1, except that this step replaces 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 1 with an equimolar amount of 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid, and 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] with an equimolar amount of 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ]]Pyrimidine substituted 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a of example 1]Pyrimidine, the rest conditions were unchanged. Finally, 0.187g of white solid is obtained, namely the product 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine carboxamide) phenoxy]-5-methyl-6-ethylpyrazolo [1,5-a ]]Pyrimidine (A)1H NMR、13C NMR andHR-MS-ESI shown below), yield 62%.
1H NMR(400MHz,DMSO-d6)δ9.19(s,1H),8.27(dd,J=7.1,1.9Hz,1H),8.10(dd,J=7.3,1.6Hz,1H),8.09~8.04(m,1H),7.99(d,J=2.3Hz,1H),7.74(dd,J=8.3,2.1Hz,1H),7.72(d,J=2.0Hz,1H),7.33~7.26(m,1H),7.07(dd,J=8.1,4.0Hz,1H),6.76(dd,J=12.2,2.6Hz,1H),6.64~6.59(m,1H),6.46(d,J=2.3Hz,1H),3.82(s,3H),3.79(s,3H),2.66~2.58(m,2H),2.54(s,3H),1.01(t,J=7.4Hz,3H).
13C NMR(101MHz,DMSO-D6)δ163.43,159.60,157.01,155.08,152.64,150.94,149.50,148.05,146.29,143.57,141.92,140.29,139.25,131.96,130.60,129.35,124.27,120.35,114.71,113.09,112.31,110.59,106.66,95.21,56.12,56.09,23.70,20.25,14.26.
HR-ESI-MS Calcd.for C29H26N5O4F[M+H]+:528.20424;found:528.20450.
Example 25
The pyridine amide compound is 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is 4-methoxyphenyl, R2Is H, R3Is 4-F, and the compound number is GMZC-Q-35.
The preparation method of the compound GMZC-Q-35 comprises the following steps:
(1) synthesis of intermediate 4-methoxybenzoyl ethyl acetate
Weighing 9g (0.0762mol) of diethyl carbonate, cooling to 0 ℃, adding 2.539g (0.106mol) of sodium hydride, stirring uniformly, adding 4.576g (0.0305mol) of 4' -methoxyacetophenone after 5 minutes, reacting for 40 minutes, transferring to normal temperature to react for 20 minutes, adding 40mL of acetic acid solution, reacting for 1 hour at normal temperature until a layer of oily matter is on the surface, and adding ethyl acetate according to the proportion of 1:1, drying the extract by using anhydrous sodium sulfate, filtering, and carrying out rotary evaporation to obtain 5.46g of oily liquid, namely the intermediate 4-methoxy benzoyl ethyl acetate with the yield of 81%.
1H NMR(400MHz,DMSO-d6)δ7.96~7.90(m,2H),7.09~7.02(m,2H),4.15~4.06(m,4H),3.85(s,3H),1.17(t,J=7.1Hz,3H);
13C NMR(101MHz,DMSO-d6)δ192.23,168.37,164.12,131.36,129.31,114.54,61.06,56.12,45.82,14.52;
HR-MS-ESI Calcd.for C12H14O4[M+H]+:223.08921;found:223.09646。
(2) Synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine
Weighing 6.7g (0.0301mol) of 4-methoxybenzoyl ethyl acetate, adding 2.5g (0.0301mol) of 3-aminopyrazole and 20mL of acetic acid, and refluxing for 6 hours at 120 ℃; and adding distilled water into the product, stirring, carrying out suction filtration, washing with absolute ethyl alcohol, and airing to obtain 4.53g of light yellow solid, namely the intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine, wherein the yield is 62%.
1H NMR(400MHz,DMSO-d6)δ12.39(s,1H),7.88(d,J=1.9Hz,1H),7.82(d,J=2.1Hz,1H),7.80(d,J=2.2Hz,1H),7.12(d,J=2.1Hz,1H),7.10(d,J=2.2Hz,1H),6.19(d,J=1.9Hz,1H),6.02(s,1H),3.83(s,3H);
13C NMR(101MHz,DMSO-d6)δ162.05,157.05,149.90,143.48,142.39,129.28,129.28,124.71,114.98,114.98,93.03,89.94,56.03;
ESI-HR-MS Calcd.for C13H11N3O2[M+H]+:242.08513;found:242.09238。
(3) Synthesis of intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine
Weighing 1.50g (0.0062mol) of 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine, adding into a round-bottom flask, adding 15mL (164.571mmol) of phosphorus oxychloride, and carrying out reflux reaction at 110 ℃ for 4 hours; after the reaction is finished, slowly pouring the reaction system into a beaker filled with 100mL of ice water while stirring under the ice bath condition, quenching phosphorus oxychloride, and after the reaction system is recovered to normal temperature, adding dichloromethane according to the ratio of 1:1, drying the extract by using anhydrous sodium sulfate, filtering, carrying out rotary evaporation on the filtrate, concentrating, and purifying by silica gel column chromatography [ using ethyl acetate and petroleum ether as eluent, wherein the ratio of ethyl acetate to petroleum ether (V: V) is 1: 8], so as to obtain 1.23g of light yellow solid, namely the intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine, and the yield is 76%.
1H NMR(400MHz,DMSO-d6)δ8.29(d,J=2.3Hz,1H),8.20(d,J=2.2Hz,1H),8.18(d,J=2.2Hz,1H),7.97(s,1H),7.07(d,J=2.2Hz,1H),7.05(d,J=2.2Hz,1H),6.83(d,J=2.3Hz,1H),3.84(s,3H).
13C NMR(101MHz,DMSO-d6)δ162.09,155.34,149.63,146.12,138.66,129.55,129.55,128.64,114.84,114.84,105.77,98.26,55.92.
HR-MS-ESI Calcd.for C13H10ClN3O[M+H]+:260.05124;found:260.05839。
(4) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine
Weighing 1g (0.00385mol) of 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine, 1.59g of potassium carbonate, 12mL of chlorobenzene, 0.73g (0.00465mol) of 2-fluoro-4-nitrophenol, reacting at 100 ℃ for 3 hours, then performing microwave reaction for 4 hours, performing spin drying, extracting by using ethyl acetate, and purifying by silica gel column chromatography (using ethyl acetate and petroleum ether as eluent, and using ethyl acetate and petroleum ether (V: V) ═ 1: 10) to obtain 0.98g of yellow-green solid, namely the intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine with the yield of 67 percent.
1H NMR(400MHz,DMSO-d6)δ8.51(dd,J=10.3,2.7Hz,1H),8.24(d,J=2.3Hz,1H),8.20(ddd,J=9.1,2.7,1.4Hz,1H),8.14(d,J=2.1Hz,1H),8.12(d,J=2.1Hz,1H),7.81(dd,J=8.9,8.2Hz,1H),7.19(s,1H),7.04(d,J=1.9Hz,1H),7.03(d,J=1.9Hz,1H),6.79(d,J=2.3Hz,1H),3.82(s,3H);
13C NMR(101MHz,DMSO-d6)δ161.98,157.39,153.91,152.59,151.40,150.87,146.38,145.88,145.80,129.59,129.29,123.01,122.07,114.46,97.23,89.81,55.89,29.56;
HR-MS-ESI Calcd.for C19H13FN4O4[M+H]+:381.09208;found:381.09932。
(5) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine
Weighing 1.5g of reduced iron powder, adding the reduced iron powder into a round-bottomed flask containing 30mL of acetic acid solution with the pH value of 2-3, activating and reacting at 90 ℃ for 1.5h, adding 1g (0.00263mol) of 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, and reacting at 90 ℃ for 6 h; filtering, extracting with ethyl acetate, drying with anhydrous sodium sulfate, spin-drying, and purifying with petroleum ether and ethyl acetate as eluent by silica gel column chromatography to obtain solid 0.436g, which is the intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine with 47% yield.
1H NMR(400MHz,DMSO-d6)δ10.01(s,1H),9.76(s,1H),8.15(d,J=2.2Hz,1H),7.94(d,J=2.0Hz,1H),7.93(d,J=2.0Hz,1H),7.33(dd,J=12.3,2.5Hz,1H),7.20~7.14(m,1H),7.09~7.03(m,1H),7.02(d,J=1.8Hz,1H),7.00(d,J=1.9Hz,1H),6.52(d,J=1.2Hz,1H),6.51(s,1H),3.79(s,3H);
13C NMR(101MHz,DMSO-d6)δ161.16,156.22,152.49,150.09,149.67,146.51,144.51,143.69,130.91,129.18,128.91,122.00,118.55,114.53,114.23,95.53,82.74,55.76,29.55;
HR-MS-ESI Calcd.for C19H15FN4O2[M+H]+:351.11790;found:351.12522。
(6) Synthesis of intermediate 6- (4-fluorophenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 1.
(7) Synthesis of the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine
0.186g (0.00085mol) of 6- (4-fluorophenyl) -2-pyridinecarboxylic acid and 0.407g of HATU were placed in a 50mL flask at 0 ℃ and 10mL of methylene chloride was added to activate the reaction for 10 minutes, then 0.277g of DIPEA was added to react for 10 minutes, and then 0.25g (0.00071mol) of 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine was added to react for 10 minutes, and the mixture was allowed to stand at room temperature for 24 hours. Adjusting the pH value to 6-7 by using a saturated sodium bicarbonate solution, extracting by using dichloromethane, drying an extract by using anhydrous sodium sulfate, filtering, and purifying by using petroleum ether and ethyl acetate as eluent through silica gel column chromatography to obtain 0.162g of a white solid, namely the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, wherein the yield is 41%.
1H NMR(400MHz,DMSO-d6)δ10.18(s,1H),8.36(dd,J=7.7,1.3Hz,1H),8.30~.27(m,1H),8.27~8.25(m,1H),8.23(d,J=1.3Hz,1H),8.23~8.22(m,1H),8.19(d,J=7.7Hz,1H),8.04(d,J=2.1Hz,1H),8.02(d,J=2.1Hz,1H),7.69(dd,J=11.7,2.4Hz,1H),7.63(t,J=8.7Hz,1H),7.54(dd,J=8.8,1.7Hz,1H),7.42(s,1H),7.38(s,1H),7.05(d,J=1.9Hz,1H),7.04(d,J=2.1Hz,1H),6.86(s,1H),6.59(d,J=2.3Hz,1H),3.81(s,3H).
13C NMR(101MHz,DMSO-d6)δ163.16,161.31,156.41,156.17,149.71,146.31,145.37,144.66,139.73,137.52,135.15,134.51,130.80,129.75,129.66,129.10,125.06,120.73,116.53,116.32,114.58,95.91,83.83,55.81,31.82,31.67,30.87,30.34,29.53,22.62,14.49.
HR-ESI-MS Calcd.for C31H21F2N5O3[M+H]+:550.16125;found:550.16882.
Example 26
The pyridine amide compound is 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is 4-methoxyphenyl, R2Is H, R3Is 3-F and 4-OCH3The compound is numbered as GMZC-Q-36.
The preparation method of the compound GMZC-Q-36 comprises the following steps:
(1) synthesizing an intermediate 4-methoxybenzoyl ethyl acetate: same as in step (1) of example 25.
(2) Synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 25.
(3) Synthesis of intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 25.
(4)5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 25.
(5) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (5) of example 25.
(6) Synthesis of intermediate 6- (3-methoxy-4-fluorophenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 2.
(7) Synthesis of the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine: the synthesis was similar to step (7) of example 25, except that 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 25 was replaced with an equimolar amount of 6- (3-methoxy-4-fluorophenyl) -2-pyridinecarboxylic acid, and the remaining conditions were unchanged. Finally, 0.195g of white solid is obtained, namely the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 47%.
1H NMR(400MHz,DMSO-d6)δ10.18(s,1H),8.31(dd,J=7.8,1.2Hz,1H),8.21(d,J=2.3Hz,1H),8.19(dd,J=7.6,1.1Hz,1H),8.16–8.13(m,1H),8.03(d,J=1.3Hz,1H),8.02(d,J=2.0Hz,1H),8.01(d,J=2.0Hz,1H),7.68(dd,J=11.7,2.4Hz,1H),7.62(t,J=8.7Hz,1H),7.54(dd,J=8.9,2.4Hz,1H),7.32(d,J=8.7Hz,1H),7.04(d,J=2.0Hz,1H),7.02(d,J=2.1Hz,1H),7.00(d,J=8.9Hz,1H),6.85(s,1H),6.58(d,J=2.3Hz,1H),3.91(s,3H),3.80(s,3H).
13C NMR(101MHz,DMSO-d6)δ163.15,161.29,156.40,151.04,149.70,149.16,149.05,146.49,146.19,145.35,139.53,135.29,135.16,130.78,129.10,128.90,125.33,124.78,123.93,120.67,114.54,95.89,83.80,56.64,55.77,31.81,31.63,30.86,30.31,29.56,22.61,14.45.
HR-ESI-MS Calcd.for C32H23F2N5O4[M+H]+:580.17181;found:580.17915.
Example 27
The pyridine amide compound is 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is 4-methoxyphenyl, R2Is H, R3Is 4-OCF3The compound is numbered as GMZC-Q-37.
The preparation method of the compound GMZC-Q-37 comprises the following steps:
(1) synthesizing an intermediate 4-methoxybenzoyl ethyl acetate: same as in step (1) of example 25.
(2) Synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 25.
(3) Synthesis of intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 25.
(4)5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 25.
(5) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (5) of example 25.
(6) Synthesis of intermediate 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 6.
(7) Synthesis of the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine: the synthesis was similar to step (7) of example 25, except that this step was carried out by substituting 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 25 with an equimolar amount of 6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions were unchanged. Finally, 0.187g of white solid is obtained, namely the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 42%.
1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),8.40(dd,J=7.8,1.2Hz,1H),8.33(d,J=2.1Hz,1H),8.32(d,J=2.1Hz,1H),8.28–8.25(m,1H),8.23(d,J=2.8Hz,1H),8.22–8.15(m,1H),8.03(d,J=2.1Hz,1H),8.02(d,J=2.1Hz,1H),7.69(dd,J=11.8,2.5Hz,1H),7.63(t,J=8.6Hz,1H),7.58–7.56(m,1H),7.56(s,1H),7.54(d,J=6.4Hz,1H),7.05(d,J=2.1Hz,1H),7.03(d,J=2.0Hz,1H),6.86(s,1H),6.59(d,J=2.3Hz,1H),3.81(s,3H).
13C NMR(101MHz,DMSO-d6)δ163.09,161.30,161.16,156.40,156.22,155.82,152.83,149.98,149.70,146.40,145.35,144.66,139.87,137.19,135.25,130.78,129.50,129.10,128.92,125.49,121.93,114.57,95.91,83.83,55.81,34.94,34.81,31.66,30.86,30.32,22.63,14.08.
HR-ESI-MS Calcd.for C32H21F4N5O4[M+H]+:616.15297;found:616.15984.
Example 28
The pyridine amide compound is 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is 4-methoxyphenyl, R2Is H, R3Is 3-CHO and 4-OCH3The compound is numbered as GMZC-Q-38.
The preparation method of the compound GMZC-Q-38 comprises the following steps:
(1) synthesizing an intermediate 4-methoxybenzoyl ethyl acetate: same as in step (1) of example 25.
(2) Synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 25.
(3) Synthesis of intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 25.
(4)5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 25.
(5) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (5) of example 25.
(6) Synthesis of intermediate 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 7.
(7) Synthesis of the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine: the synthesis was similar to step (7) of example 25, except that this step was carried out in the same manner as in example 25 except that 6- (4-fluorophenyl) -2-pyridinecarboxylic acid was replaced with an equimolar amount of 6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions were changed. Finally, 0.180g of white solid is obtained, namely the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 44%.
1H NMR(400MHz,DMSO-d6)δ10.43(s,1H),10.20(s,1H),8.53(d,J=2.4Hz,1H),8.49(dd,J=8.8,2.5Hz,1H),8.37(dd,J=7.8,1.2Hz,1H),8.22(s,1H),8.20(d,J=7.2Hz,1H),8.18–8.15(m,1H),8.04(d,J=2.2Hz,1H),8.02(d,J=2.1Hz,1H),7.69(dd,J=11.8,2.5Hz,1H),7.63(t,J=8.7Hz,1H),7.54(dd,J=9.1,1.8Hz,1H),7.42(d,J=8.9Hz,1H),7.05(d,J=2.1Hz,1H),7.03(d,J=2.0Hz,1H),6.88(s,1H),6.59(d,J=2.3Hz,1H),4.01(s,3H),3.81(s,3H).
13C NMR(101MHz,DMSO-d6)δ189.59,175.05,168.37,163.11,161.29,156.39,155.91,152.84,149.70,146.29,145.35,144.63,139.67,137.63,135.07,130.77,130.45,129.11,128.91,126.81,124.79,114.56,113.89,83.81,56.86,55.79,31.83,31.66,30.32,29.58,24.33,22.63,14.49.
HR-ESI-MS Calcd.for C33H24FN5O5[M+H]+:590.17615;found:590.18347.
Example 29
The pyridine amide compound is 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is 4-methoxyphenyl, R2Is H, R3Is 3-OCH3And 4-OCH3The compound is numbered as GMZC-Q-39.
The preparation method of the compound GMZC-Q-39 comprises the following steps:
(1) synthesizing an intermediate 4-methoxybenzoyl ethyl acetate: same as in step (1) of example 25.
(2) Synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 25.
(3) Synthesis of intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 25.
(4)5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 25.
(5) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (5) of example 25.
(6) Synthesis of intermediate 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 8.
(7) Synthesis of the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine: the synthesis was similar to step (7) of example 25, except that 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 25 was replaced with an equimolar amount of 6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions were unchanged. Finally, 0.183g of white solid was obtained, which was the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 43%.
1H NMR(400MHz,DMSO-d6)δ10.19(s,1H),8.33(dd,J=7.6,1.3Hz,1H),8.22(d,J=2.3Hz,1H),8.19–8.16(m,1H),8.16–8.11(m,1H),8.04(d,J=2.0Hz,1H),8.02(d,J=2.0Hz,1H),7.82–7.78(m,1H),7.78(d,J=2.0Hz,1H),7.69(dd,J=11.8,2.3Hz,1H),7.63(t,J=8.7Hz,1H),7.54(dd,J=8.8,1.7Hz,1H),7.12(d,J=8.4Hz,1H),7.05(d,J=2.0Hz,1H),7.03(d,J=1.7Hz,1H),6.87(s,1H),6.59(d,J=2.2Hz,1H),3.87(s,3H),3.84(s,3H),3.81(s,3H).
13C NMR(101MHz,DMSO-d6)δ163.25,161.30,157.07,156.41,150.99,149.70,149.52,146.13,145.35,144.64,139.30,135.20,130.80,130.59,129.10,125.35,124.62,124.38,120.66,120.38,114.57,112.92,112.34,110.65,95.90,83.82,56.15,56.11,55.80,31.67,30.87,30.34,29.56.
HR-ESI-MS Calcd.for C33H26FN5O5[M+H]+:592.19180;found:592.19939.
Example 30
The pyridine amide compound is 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridine amido phenoxy)]Pyrazolo [1,5-a]Pyrimidines of the general structural formula (I), R1Is 4-methoxyphenyl, R2Is H, R3Is 3-OCH3And 5-OCH3The compound is numbered as GMZC-Q-40.
The preparation method of the compound GMZC-Q-40 comprises the following steps:
(1) synthesizing an intermediate 4-methoxybenzoyl ethyl acetate: same as in step (1) of example 25.
(2) Synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine: same as in step (2) of example 25.
(3) Synthesis of intermediate 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine: same as in step (3) of example 25.
(4)5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (4) of example 25.
(5) Synthesis of intermediate 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine: same as in step (5) of example 25.
(6) Synthesis of intermediate 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid: same as in step (5) of example 9.
(7) Synthesis of the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine: the synthesis was similar to step (7) of example 25, except that 6- (4-fluorophenyl) -2-pyridinecarboxylic acid of example 25 was replaced with an equimolar amount of 6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxylic acid, and the remaining conditions were unchanged. Finally obtaining white0.190g of a colored solid, i.e., the product 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridylaminophenoxy)]Pyrazolo [1,5-a]Pyrimidine (A)1H NMR、13C NMR and HR-MS-ESI are shown below), yield 46%.
1H NMR(400MHz,DMSO-d6)δ10.03(s,1H),9.78(s,1H),8.16(d,J=2.2Hz,1H),7.94(d,J=1.9Hz,1H),7.93(d,J=1.9Hz,1H),7.74–7.70(m,1H),7.70–7.67(m,1H),7.67–7.63(m,1H),7.52–7.34(m,1H),7.34–7.30(m,1H),7.26–7.16(m,1H),7.16–7.05(m,1H),7.03(s,1H),7.02(s,1H),7.00(s,1H),6.52–6.52(m,1H),6.51(s,1H),4.21(t,J=6.6Hz,3H),3.90–3.80(m,3H),3.79(s,3H).
13C NMR(101MHz,DMSO-d6)δ167.50,161.18,156.21,150.09,149.64,146.52,144.53,143.69,143.57,132.22,132.05,130.89,129.19,128.92,122.01,118.56,118.52,114.54,114.24,114.04,95.52,82.76,65.56,55.93,55.77,31.82,31.66,30.52,30.33,29.55,22.63,19.18,14.08.
HR-ESI-MS Calcd.for C33H26FN5O5[M+H]+:592.19280;found:592.19913.
Table 1 shows the pyridine amides obtained in examples 1 to 30.
Table 1 Compounds and corresponding substituents
Antitumor Activity test
The antitumor activity of the picolinamide compounds with the serial numbers of GMZC-Q-1 to GMZC-Q-40 is researched.
1. Pretreatment of pharmaceutical agents
Preparing a compound to be tested: the compound with the corresponding number is dissolved into stock solution with the concentration of 100mM by DMSO, and the stock solution is diluted to 0-500 mu M by serum-free culture medium during measurement and is used as the reagent.
2. Experimental methods
(1) Testing of antitumor Activity Using MDA-MB-231 cells
Using high-glucose DMEM medium, 10% south American Fetal Bovine Serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin, 5% CO at 37 ℃2Culturing in an incubator. When the MDA-MB-231 cells are in good state, the cells are inoculated into a 96-well plate, the density is 4000 per well, and the temperature is 37 ℃ and the CO content is 5 percent2The culture is continued in the incubator, and after the attachment is complete, 100 mul of serum-free culture medium containing different compound concentrations is added. After 72h incubation, the medium was aspirated off, 110. mu.L of a mixture containing 10. mu.L of CCK8 and 100. mu.L of medium was added and incubation continued for 1-4 h. Cabozantinib and 5-fluorourcral are selected as positive control drugs, and a blank group and a zero-setting group are set simultaneously. The absorbance was measured at 450nm and 630nm using a microplate reader. The data obtained were processed to calculate the inhibition rate of each compound. The inhibition was plotted against the corresponding concentration of the different compounds, and the data were processed using SPSS19.0 statistical software to calculate IC50The value is obtained. The calculation formula of the inhibition rate is as follows: [1- (Experimental group-background group)/(blank group-zero adjustment group)]X 100%. Each experimental group was set with 6 replicates and the experimental results are expressed as mean ± SD of 3 independent experiments.
(2) Testing of antitumor Activity Using MCF-7 cells
Using high-glucose DMEM medium, 10% south American Fetal Bovine Serum (FBS), 1% double antibody (100U/mL penicillin and 100mg/mL streptomycin), 5% CO at 37 ℃2Culturing in an incubator. When MCF-7 cells are in good state, the cells are inoculated into a 96-well plate at 100 uL/well and the cell density of 4000/well, and 5% CO is carried out at 37 DEG C2And (3) continuing culturing in the incubator, adding 100 mu L of serum-free culture medium containing different compound concentrations after the attachment is complete, incubating for 72h, sucking the culture solution, adding 110 mu L of mixed solution containing 10 mu L of CCK8 and 100 mu L of culture medium, and continuing incubating for 2.5 h. The absorbance was measured at 450nm and 630nm using a microplate reader. From the obtained OD values, the inhibition ratios corresponding to the set concentrations were calculated, and the IC50 values were calculated using SPSS19.0 software. Inhibition rate ═ 1- (experimental group-background group)/(blank group-zero adjustment group)]X 100%. Each experimental group was set to 6 replicates and the results are expressed as mean ± SD of three independent experiments.
(3) Anti-tumor activity test using A549 cells
Using RPMI Medium 1640 Medium, 10% south American Fetal Bovine Serum (FBS), 1% double antibody (100U/mL penicillin and 100mg/mL streptomycin), 5% CO at 37 deg.C2Culturing in an incubator. When the A549 cells are in good state, inoculating the cells into a 96-well plate at 100 uL/well and 6000 cells/well, and carrying out 5% CO treatment at 37 DEG C2And (3) continuing culturing in the incubator, adding 100 mu L of serum-free culture medium containing different compound concentrations after the attachment is complete, incubating for 72h, sucking the culture solution, adding 110 mu L of mixed solution containing 10 mu L of CCK8 and 100 mu L of culture medium, and continuing incubating for 1.5 h. The absorbance was measured at 450nm and 630nm using a microplate reader. From the obtained OD values, the inhibition ratios corresponding to the set concentrations were calculated, and the IC50 values were calculated using SPSS19.0 software. Inhibition rate ═ 1- (experimental group-background group)/(blank group-zero adjustment group)]X 100%. Each experimental group was set to 6 replicates and the results are expressed as mean ± SD of three independent experiments.
(4) Antitumor activity test Using Hep G2 cells
Using high-sugar DMEM medium, 10% south American Fetal Bovine Serum (FBS), 1% double antibody (100U/mL penicillin and 100mg/mL streptomycin), 5% CO at 37 ℃2Culturing in an incubator. When the Hep G2 cells are in good condition, the cells are inoculated into a 96-well plate at 100 uL/well and 6000 cells/well at 37 ℃ with 5% CO2And (3) continuing culturing in the incubator, adding 100 mu L of serum-free culture medium containing different compound concentrations after the attachment is complete, incubating for 72h, sucking the culture solution, adding 110 mu L of mixed solution containing 10 mu L of CCK8 and 100 mu L of culture medium, and continuing incubating for 2.5 h. The absorbance was measured at 450nm and 630nm using a microplate reader. From the obtained OD values, the inhibition ratios corresponding to the set concentrations were calculated, and the IC50 values were calculated using SPSS software. Inhibition rate ═ 1- (experimental group-background group)/(blank group-zero adjustment group)]X 100%. Each experimental group was set to 6 replicates and the results are expressed as mean ± SD of three independent experiments.
3. Results of the experiment
The results of the cell experiments are shown in table 2.
TABLE 2 antitumor Activity test results of picolinamide compounds of the present invention
The experimental results show that the pyridine amide compounds provided by the invention can inhibit or kill tumor cells, the anti-tumor effect of part of the compounds is superior to that of the marketed drugs 5-fluorourcil and Cabozantinib, the compounds have good anti-tumor activity, and the compounds can be used for preparing drugs for treating tumors such as human breast cancer, human lung cancer and human liver cancer, and can effectively treat tumors.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (5)
1. A picolinamide compound characterized in that the picolinamide compound is 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-picolinamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-picolinamide) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6 '-methoxy- [2,3' -bipyridine ] -6-carboxamido) phenoxy ] -5-methylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxybenzene) benzamide Yl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5, 6-dimethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-fluoro-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridinecarboxamido) phenoxy ] -5-methyl-6-ethylpyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-fluorophenyl) -2-pyridinecarboxamido phenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-methoxy-4-fluorophenyl) -2-pyridinecarboxamido phenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (4-trifluoromethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3-formyl-4-methoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 4-dimethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine, 5- (4-methoxyphenyl) -7- [ 2-fluoro-4- (6- (3, 5-dimethoxyphenyl) -2-pyridylaminophenoxy) ] pyrazolo [1,5-a ] pyrimidine.
2. The process for producing a picolinamide compound as defined in claim 1, which comprises the steps of:
(1) synthesis of intermediates 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine:
taking 3-aminopyrazole and ethyl acetoacetate or ethyl 2-methylacetoacetate or ethyl 2-ethylacetoacetate, adding glacial acetic acid as a reaction solvent, heating and stirring for reaction, and separating and purifying after the reaction is finished to obtain solid products, namely the 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine;
(2) synthesis of intermediate 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine:
taking 4-methoxybenzoyl ethyl acetate and 3-aminopyrazole, adding acetic acid as a reaction solvent, carrying out reflux reaction, and separating and purifying after the reaction is finished to obtain a solid product, namely the 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine;
(3) synthesis of intermediates 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine:
taking 5-methyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-hydroxy-pyrazolo [1,5-a ] pyrimidine, N-dimethylaniline or diethylamine or triethylamine and phosphorus oxychloride, reacting for 24-48 h at 20-60 ℃, slowly pouring the reaction system into ice water while stirring under the ice bath condition, adjusting the pH value to be neutral after recovering the normal temperature, separating and purifying to obtain oily liquid products, namely the 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine and 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine;
or taking 5- (4-methoxyphenyl) -7-hydroxy-pyrazolo [1,5-a ] pyrimidine and phosphorus oxychloride, carrying out reflux reaction for 4-8 h at 110-130 ℃, slowly pouring a reaction system into ice water while stirring under an ice bath condition, recovering to normal temperature, and carrying out separation and purification to obtain a solid product, namely the 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine;
(4) synthesis of intermediates 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine:
dissolving 5-methyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7-chloro-pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7-chloro-pyrazolo [1,5-a ] pyrimidine in chlorobenzene or toluene or xylene, adding 2-fluoro-4-nitrophenol, heating, stirring, reacting, separating and purifying to obtain a solid product, namely the 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine, or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine;
(5) synthesis of intermediates 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine:
adding acetic acid solution or formic acid solution or ammonium chloride solution, and 5-methyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-nitrophenoxy) -pyrazolo [1,5-a ] pyrimidine into reduced iron powder, separating and purifying after the reaction is finished, the obtained solid product is the 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine, 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine;
(6) synthesizing an intermediate 6- (phenyl) -2-pyridinecarboxylic acid compound or 6- (pyridyl) -2-pyridinecarboxylic acid compound:
taking 2-bromo-6-pyridinecarboxylic acid, substituted phenylboronic acid or phenylboronic acid pinacol ester, cesium carbonate and Pd (PPh)3)4Or PdCl2Or PdCl2(dppf) or Pd (OAc)2Or Pd (PPh)3)2Cl2Carrying out reflux reaction under the protection of nitrogen, and separating and purifying after the reaction is finished to obtain a solid product, namely the 6- (phenyl) -2-pyridine carboxylic acid compound or the 6- (pyridyl) -2-pyridine carboxylic acid compound;
(7) synthesizing the pyridine amide compound:
taking 6- (phenyl) -2-pyridine carboxylic acid compounds or 6- (pyridyl) -2-pyridine carboxylic acid compounds, 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethylurea hexafluorophosphate, N, N-diisopropylethylamine, and 5-methyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5, 6-dimethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5-methyl-6-ethyl-7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine or 5- (4-methoxyphenyl) -7- (2-fluoro-4-aminophenoxy) -pyrazolo [1,5-a ] pyrimidine reacts for 8-25 h at the temperature of 0-60 ℃, and is separated and purified after the reaction is finished, so that the solid product is the pyridine amide compound.
3. The process for producing a picolinamide compound as defined in claim 2, wherein the heating and stirring reaction in step (1) is: stirring and reacting for 1-3 h at 100-140 ℃; the reflux reaction in the step (2) is as follows: carrying out reflux reaction at 110-130 ℃ for 4-8 h; the heating stirring reaction in the step (4) is as follows: reacting for 1-10 h at 100-130 ℃; the reaction of the step (5) is as follows: reacting for 3-8 h at 80-100 ℃; the reflux reaction in the step (6) is as follows: reflux reaction is carried out for 1-6 h at 70-110 ℃.
4. The use of picolinamide compounds as defined in claim 1 in the preparation of anti-tumor medicaments.
5. An antitumor agent comprising the picolinamide compound as defined in claim 1 and a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010257388.9A CN111440174B (en) | 2020-04-02 | 2020-04-02 | Pyridine amide compound and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010257388.9A CN111440174B (en) | 2020-04-02 | 2020-04-02 | Pyridine amide compound and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111440174A CN111440174A (en) | 2020-07-24 |
CN111440174B true CN111440174B (en) | 2021-07-09 |
Family
ID=71648317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010257388.9A Expired - Fee Related CN111440174B (en) | 2020-04-02 | 2020-04-02 | Pyridine amide compound and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111440174B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101248059A (en) * | 2005-04-27 | 2008-08-20 | 安姆根有限公司 | Substituted amide derivatives as protein kinase inhibitors |
WO2013038362A1 (en) * | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
CN105732616A (en) * | 2016-01-08 | 2016-07-06 | 江西科技师范大学 | Pyrrolopyridine compounds containing biaryl amide structure, preparation method and applications thereof |
CN108727386A (en) * | 2018-07-16 | 2018-11-02 | 广州医科大学 | A kind of Pyrazolopyrimidines and its preparation method and application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0628559B1 (en) * | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Pyrimidine compounds and their use as pharmaceuticals |
-
2020
- 2020-04-02 CN CN202010257388.9A patent/CN111440174B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101248059A (en) * | 2005-04-27 | 2008-08-20 | 安姆根有限公司 | Substituted amide derivatives as protein kinase inhibitors |
WO2013038362A1 (en) * | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
CN105732616A (en) * | 2016-01-08 | 2016-07-06 | 江西科技师范大学 | Pyrrolopyridine compounds containing biaryl amide structure, preparation method and applications thereof |
CN108727386A (en) * | 2018-07-16 | 2018-11-02 | 广州医科大学 | A kind of Pyrazolopyrimidines and its preparation method and application |
Non-Patent Citations (2)
Title |
---|
吡唑并[1,5-a]嘧啶类 c-Met 激酶抑制剂的合成及生物活性研究;倪春燕 等;《Chinese Journal of Organic Chemistry》;20120827;第32卷;第2294-2299页 * |
靶向 HGF/c- Met 信号通路的抗体类抗肿瘤药物研究进展;郭斌生 等;《药物生物技术》;20171231;第24卷(第6期);第534-540页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111440174A (en) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111712498A (en) | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | |
CN111393404B (en) | Benzothiophene compounds, and pharmaceutical composition and application thereof | |
EP3705480B1 (en) | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof | |
CN108727386A (en) | A kind of Pyrazolopyrimidines and its preparation method and application | |
CN112300196A (en) | Piperidine condensed ring compound, preparation method and application | |
CN113024544A (en) | Cyano-containing heterocyclic compound and application thereof | |
CN113527300B (en) | Bruton's tyrosine protein kinase inhibitor | |
CN109810100B (en) | Benzofuran-containing PARP-1 and PI3K dual-target inhibitors | |
CN111440174B (en) | Pyridine amide compound and preparation method and application thereof | |
CN103910643B (en) | Anti-cancer activity ketone derivative as well as synthetic method and application thereof | |
CN116768902A (en) | Substituted phenol hydroxyl phenyl pyrrolopyrimidine compound and preparation method and application thereof | |
CN110804059A (en) | Carbamate compound, pharmaceutical composition and application thereof | |
CN101654401B (en) | Asymmetrical biphenyl compounds, medicinal compositions containing same and application of medicinal compositions | |
CN109384784B (en) | Sulfonamide derivative, preparation method thereof and application thereof in medicine | |
CN109824640A (en) | A kind of coumarin kind compound and its pharmaceutical composition, preparation method and application | |
CN107573336B (en) | Benzoheterocycle-formamide-pyridone derivative and preparation method and application thereof | |
CN115991705A (en) | 3- (1H pyrrolo [2,3-b ] pyridin-5-yl) benzoyl derivatives, preparation and application thereof | |
CN106008475B (en) | Coumarin NEDD8 activating enzyme inhibitor | |
CN106588920B (en) | 1,3- diazacyclos simultaneously [1,2-a] quinolines and preparation method thereof and antitumor application thereof | |
CN105541810B (en) | Coumarin NEDD8 activating enzyme inhibitor and preparation method and application thereof | |
CN112174958B (en) | Pyrido [2,3-d ] pyrimidine compound and preparation method and application thereof | |
CN114634521A (en) | DNA-PK selective inhibitor and preparation method and application thereof | |
CN116102533A (en) | Aromatic heterocyclic compound and application thereof | |
CN111393405B (en) | Fluorine-containing substituted benzothiophene compounds, and pharmaceutical composition and application thereof | |
CN103254203B (en) | Five yuan of urea rings coumarin derivative or its officinal salt and purposes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210709 |
|
CF01 | Termination of patent right due to non-payment of annual fee |